thiophenes - Ontology Report - Rat Genome Database

Submit Data | Help | Video Tutorials | News | Publications | Download | REST API | Citing RGD | Contact

CHEBI ONTOLOGY - ANNOTATIONS

{{ watchLinkText }}

The Chemical Entities of Biological Interest (ChEBI) ontology is downloaded weekly from EMBL-EBI at http://www.ebi.ac.uk/chebi/. The data is made available under the Creative Commons License (CC BY 3.0, http://creativecommons.org/licenses/by/3.0/). For more information see: Degtyarenko et al. (2008) ChEBI: a database and ontology for chemical entities of biological interest. Nucleic Acids Res. 36, D344–D350.

Term:	thiophenes	go back to main search page
Accession:	CHEBI:26961	browse the term
Definition:	Compounds containing at least one thiophene ring.
Synonyms:	alt_id:	MESH:D013876
	xref_mesh:	MESH:D013876

show annotations for term's descendants Sort by:
Rat (220) Mouse (221) Human (227) Chinchilla (0) Bonobo (0) Dog (0) Squirrel (0) Pig (0) Green Monkey (0) Naked Mole-rat (0) All
Genes (220)

thiophenes

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

ATP binding cassette subfamily E member 1

multiple interactions

Thiophenes analog promotes the reaction [Tretinoin results in decreased expression of ABCE1 mRNA]

NCBI chr19:28,205,566...28,230,489
Ensembl chr19:28,205,555...28,230,489

G

annexin A1

multiple interactions

Thiophenes analog promotes the reaction [Tretinoin results in increased expression of ANXA1 mRNA]

NCBI chr 1:217,861,175...217,877,205
Ensembl chr 1:217,861,175...217,877,343

G

baculoviral IAP repeat-containing 2

multiple interactions

Thiophenes analog promotes the reaction [Tretinoin results in increased expression of BIRC2 mRNA]

NCBI chr 8:4,968,856...4,989,325
Ensembl chr 8:4,968,842...4,988,732

G

carbonic anhydrase 1

decreases activity

Thiophenes analog results in decreased activity of CA1 protein

NCBI chr 2:86,829,436...86,872,209
Ensembl chr 2:86,861,897...86,872,208

G

carbonic anhydrase 2

decreases activity

Thiophenes analog results in decreased activity of CA2 protein

NCBI chr 2:86,741,625...86,756,766
Ensembl chr 2:86,741,626...86,756,818

G

Cd53 molecule

multiple interactions

Thiophenes analog promotes the reaction [Tretinoin results in increased expression of CD53 mRNA]

NCBI chr 2:194,352,139...194,399,668
Ensembl chr 2:194,352,139...194,399,657

G

cyclin-dependent kinase inhibitor 1A

multiple interactions

Thiophenes analog promotes the reaction [Tretinoin results in increased expression of CDKN1A protein]

NCBI chr20:7,149,177...7,159,727
Ensembl chr20:7,149,217...7,159,585

G

cyclin-dependent kinase inhibitor 1B

multiple interactions

Thiophenes analog promotes the reaction [Tretinoin results in increased expression of CDKN1B protein]

NCBI chr 4:167,760,067...167,765,177
Ensembl chr 4:167,760,181...167,764,982

G

chromosome segregation 1 like

multiple interactions

Thiophenes analog promotes the reaction [Tretinoin results in decreased expression of CSE1L mRNA]

NCBI chr 3:155,641,104...155,678,866
Ensembl chr 3:155,641,166...155,678,865

G

DEAD-box helicase 10

multiple interactions

Thiophenes analog promotes the reaction [Tretinoin results in decreased expression of DDX10 mRNA]

NCBI chr 8:53,488,656...53,643,373
Ensembl chr 8:53,488,656...53,643,373

G

DEAD-box helicase 18

multiple interactions

Thiophenes analog promotes the reaction [Tretinoin results in decreased expression of DDX18 mRNA]

NCBI chr13:32,729,697...32,743,161
Ensembl chr13:32,729,700...32,743,161

G

eukaryotic translation initiation factor 3, subunit B

multiple interactions

Thiophenes analog promotes the reaction [Tretinoin results in decreased expression of EIF3B mRNA]

NCBI chr12:14,196,403...14,220,865
Ensembl chr12:14,196,403...14,220,886

G

eukaryotic translation initiation factor 3, subunit C

multiple interactions

Thiophenes analog promotes the reaction [Tretinoin results in decreased expression of EIF3C mRNA]

NCBI chr 1:181,134,604...181,152,489
Ensembl chr 1:181,134,604...181,152,493

G

eukaryotic translation initiation factor 4E

multiple interactions

Thiophenes analog promotes the reaction [Tretinoin results in decreased expression of EIF4E mRNA]

NCBI chr 2:227,066,519...227,099,261
Ensembl chr 2:227,066,673...227,098,683

G

eukaryotic translation initiation factor 4E binding protein 1

multiple interactions

Thiophenes analog promotes the reaction [Tretinoin results in decreased expression of EIF4EBP1 mRNA]

NCBI chr16:64,792,595...64,805,984
Ensembl chr16:64,790,226...64,805,984

G

growth arrest specific 7

multiple interactions

Thiophenes analog promotes the reaction [Tretinoin results in increased expression of GAS7 mRNA]

NCBI chr10:52,152,718...52,383,283
Ensembl chr10:52,152,493...52,383,276

G

growth factor receptor bound protein 10

multiple interactions

Thiophenes analog promotes the reaction [Tretinoin results in decreased expression of GRB10 mRNA]

NCBI chr14:86,495,051...86,602,800
Ensembl chr14:86,495,054...86,602,806

G

glutathione S-transferase pi 1

multiple interactions

Thiophenes analog promotes the reaction [Tretinoin results in increased expression of GSTP1 mRNA]

NCBI chr 1:201,337,762...201,340,230
Ensembl chr 1:201,321,672...201,340,226

G

histone deacetylase 1

multiple interactions

Thiophenes analog promotes the reaction [Tretinoin results in increased expression of HDAC1 mRNA]

NCBI chr 5:141,853,992...141,881,057
Ensembl chr 5:141,853,989...141,881,111

G

histamine receptor H3

multiple interactions

Thiophenes analog binds to and results in decreased activity of HRH3 protein

NCBI chr 3:167,191,551...167,196,642
Ensembl chr 3:167,191,558...167,196,642

G

interferon-induced protein with tetratricopeptide repeats 3

multiple interactions

Thiophenes analog promotes the reaction [Tretinoin results in increased expression of IFIT3 mRNA]

NCBI chr 1:232,114,166...232,119,311
Ensembl chr 1:232,114,166...232,119,307

G

interferon induced transmembrane protein 1

multiple interactions

Thiophenes analog promotes the reaction [Tretinoin results in increased expression of IFITM1 mRNA]

NCBI chr 1:196,067,163...196,069,169
Ensembl chr 1:196,067,963...196,069,169

G

interleukin 6

multiple interactions

Thiophenes inhibits the reaction [KEAP1 gene mutant form promotes the reaction [lipopolysaccharide, E coli O55-B5 results in increased expression of IL6 mRNA]]

NCBI chr 4:5,214,602...5,219,178
Ensembl chr 4:5,213,394...5,219,178

G

integrin subunit alpha 6

multiple interactions

Thiophenes analog promotes the reaction [Tretinoin results in increased expression of ITGA6 mRNA]

NCBI chr 3:56,604,512...56,689,428
Ensembl chr 3:56,617,268...56,689,428

G

Kelch-like ECH-associated protein 1

multiple interactions

Thiophenes inhibits the reaction [KEAP1 gene mutant form promotes the reaction [lipopolysaccharide, E coli O55-B5 results in increased expression of IL6 mRNA]]

NCBI chr 8:19,768,375...19,777,862
Ensembl chr 8:19,768,375...19,777,862

G

lysosomal-associated membrane protein 2

multiple interactions

Thiophenes analog promotes the reaction [Tretinoin results in increased expression of LAMP2 mRNA]

NCBI chr X:117,173,097...117,222,090
Ensembl chr X:117,057,606...117,260,522

G

lymphocyte antigen 6 family member E

multiple interactions

Thiophenes analog promotes the reaction [Tretinoin results in increased expression of LY6E mRNA]

NCBI chr 7:106,935,530...106,939,689
Ensembl chr 7:106,935,761...106,939,689

G

myeloperoxidase

multiple interactions

Thiophenes analog promotes the reaction [Tretinoin results in decreased expression of MPO mRNA]

NCBI chr10:72,594,883...72,608,862
Ensembl chr10:72,594,661...72,604,819

G

MYC proto-oncogene, bHLH transcription factor

multiple interactions

Thiophenes analog promotes the reaction [Tretinoin results in decreased expression of MYC mRNA]

NCBI chr 7:93,593,705...93,598,633
Ensembl chr 7:93,593,705...93,598,630

G

myosin, heavy chain 9

multiple interactions

Thiophenes analog promotes the reaction [Tretinoin results in increased expression of MYH9 mRNA]

NCBI chr 7:109,343,718...109,424,457
Ensembl chr 7:109,343,706...109,424,457

G

NEDD8 activating enzyme E1 subunit 1

multiple interactions

Thiophenes analog promotes the reaction [Tretinoin results in decreased expression of NAE1 mRNA]

NCBI chr19:446,015...472,145
Ensembl chr19:446,000...472,371

G

N-myc (and STAT) interactor

multiple interactions

Thiophenes analog promotes the reaction [Tretinoin results in increased expression of NMI mRNA]

NCBI chr 3:36,415,607...36,439,716
Ensembl chr 3:36,415,607...36,439,498

G

protein phosphatase, Mg2+/Mn2+ dependent, 1G

multiple interactions

Thiophenes analog promotes the reaction [Tretinoin results in decreased expression of PPM1G mRNA]

NCBI chr 6:25,153,556...25,173,763
Ensembl chr 6:25,153,556...25,173,761

G

protein arginine methyltransferase 1

multiple interactions

Thiophenes analog promotes the reaction [Tretinoin results in decreased expression of PRMT1 mRNA]

NCBI chr 1:95,458,853...95,468,176
Ensembl chr 1:95,458,850...95,468,345

G

Rab geranylgeranyltransferase subunit beta

multiple interactions

Thiophenes analog promotes the reaction [Tretinoin results in decreased expression of RABGGTB mRNA]

NCBI chr 2:242,844,758...242,850,951
Ensembl chr 2:242,844,762...242,851,050

G

retinoic acid receptor, alpha

multiple interactions

Thiophenes analog promotes the reaction [Tretinoin results in increased expression of RARA mRNA alternative form]

NCBI chr10:83,883,490...83,928,932
Ensembl chr10:83,893,384...83,928,142

G

RB transcriptional corepressor 1

multiple interactions

Thiophenes analog promotes the reaction [Tretinoin results in decreased phosphorylation of RB1 protein]

NCBI chr15:48,371,295...48,502,473
Ensembl chr15:48,371,296...48,502,302

G

RNA sensor RIG-1

multiple interactions

Thiophenes analog promotes the reaction [Tretinoin results in increased expression of RIGI mRNA]

NCBI chr 5:55,321,351...55,369,947
Ensembl chr 5:55,321,235...55,370,819

G

RuvB-like AAA ATPase 2

multiple interactions

Thiophenes analog promotes the reaction [Tretinoin results in decreased expression of RUVBL2 mRNA]

NCBI chr 1:95,902,014...95,915,247
Ensembl chr 1:95,901,701...95,915,342

G

signal transducer and activator of transcription 1

multiple interactions

Thiophenes analog promotes the reaction [Tretinoin results in increased expression of STAT1 mRNA]

NCBI chr 9:49,419,561...49,459,969
Ensembl chr 9:49,419,340...49,588,540

G

serine/threonine kinase 10

multiple interactions

Thiophenes analog promotes the reaction [Tretinoin results in increased expression of STK10 mRNA]

NCBI chr10:17,117,860...17,212,065
Ensembl chr10:17,117,878...17,212,061

G

transglutaminase 2

multiple interactions

Thiophenes analog promotes the reaction [Tretinoin results in increased expression of TGM2 mRNA]

NCBI chr 3:146,772,684...146,801,924
Ensembl chr 3:146,772,687...146,801,981

G

TNF superfamily member 10

multiple interactions

Thiophenes analog promotes the reaction [Tretinoin results in increased expression of TNFSF10 mRNA]

NCBI chr 2:110,199,835...110,227,239
Ensembl chr 2:110,207,916...110,225,135

(S)-duloxetine hydrochloride

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

androgen receptor

multiple interactions

Duloxetine Hydrochloride binds to and results in decreased activity of AR protein

NCBI chr X:63,104,771...63,273,934
Ensembl chr X:63,104,771...63,273,925

G

cytochrome P450, family 17, subfamily a, polypeptide 1

decreases activity
multiple interactions

Duloxetine Hydrochloride results in decreased activity of CYP17A1 protein
Duloxetine Hydrochloride inhibits the reaction [[CYP17A1 protein results in increased hydroxylation of Pregnenolone] which results in increased chemical synthesis of 17-alpha-Hydroxypregnenolone]; Duloxetine Hydrochloride inhibits the reaction [[CYP17A1 protein results in increased hydroxylation of Progesterone] which results in increased chemical synthesis of 17-alpha-Hydroxyprogesterone]; Duloxetine Hydrochloride inhibits the reaction [[CYP17A1 protein results in increased metabolism of 17-alpha-Hydroxypregnenolone] which results in increased chemical synthesis of Dehydroepiandrosterone]; Duloxetine Hydrochloride inhibits the reaction [[CYP17A1 protein results in increased metabolism of 17-alpha-Hydroxyprogesterone] which results in increased chemical synthesis of Androstenedione]; Duloxetine Hydrochloride inhibits the reaction [CYP17A1 protein results in increased hydroxylation of Pregnenolone]; Duloxetine Hydrochloride inhibits the reaction [CYP17A1 protein results in increased hydroxylation of Progesterone]; Duloxetine Hydrochloride inhibits the reaction [CYP17A1 protein results in increased metabolism of 17-alpha-Hydroxypregnenolone]; Duloxetine Hydrochloride inhibits the reaction [CYP17A1 protein results in increased metabolism of 17-alpha-Hydroxyprogesterone]

NCBI chr 1:245,535,462...245,543,148
Ensembl chr 1:245,535,462...245,541,573

G

cytochrome P450, family 1, subfamily a, polypeptide 1

decreases activity

Duloxetine Hydrochloride results in decreased activity of CYP1A1 protein

NCBI chr 8:58,096,021...58,102,130
Ensembl chr 8:58,096,077...58,102,125

G

cytochrome P450, family 1, subfamily a, polypeptide 2

multiple interactions

[furafylline results in decreased activity of CYP1A2 protein] which results in decreased glutathionylation of Duloxetine Hydrochloride; CYP1A2 protein results in increased activity of and results in increased glutathionylation of Duloxetine Hydrochloride

NCBI chr 8:58,075,367...58,082,255
Ensembl chr 8:58,075,367...58,082,312

G

cytochrome P450, family 1, subfamily b, polypeptide 1

decreases activity

Duloxetine Hydrochloride results in decreased activity of CYP1B1 protein

NCBI chr 6:15,342,312...15,350,886
Ensembl chr 6:15,342,344...15,350,917

G

cytochrome P450, family 2, subfamily d, polypeptide 4

multiple interactions

[Quinidine results in decreased activity of CYP2D6 protein] which results in decreased glutathionylation of Duloxetine Hydrochloride; CYP2D6 protein results in increased activity of and results in increased glutathionylation of Duloxetine Hydrochloride

NCBI chr 7:113,882,584...113,891,754
Ensembl chr 7:113,881,618...113,891,759

G

heme oxygenase 1

increases expression

Duloxetine Hydrochloride results in increased expression of HMOX1 mRNA

NCBI chr19:13,466,287...13,474,082
Ensembl chr19:13,467,244...13,474,079

G

potassium voltage-gated channel subfamily H member 2

decreases activity

Duloxetine Hydrochloride results in decreased activity of KCNH2 protein

NCBI chr 4:10,826,834...10,859,009
Ensembl chr 4:10,826,928...10,859,008

G

potassium inwardly-rectifying channel, subfamily J, member 3

multiple interactions

Duloxetine Hydrochloride results in decreased activity of [KCNJ3 mRNA co-treated with KCNJ5 mRNA]; Duloxetine Hydrochloride results in decreased activity of [KCNJ3 mRNA co-treated with KCNJ6 mRNA]

NCBI chr 3:39,944,896...40,106,646
Ensembl chr 3:39,945,351...40,109,124

G

potassium inwardly-rectifying channel, subfamily J, member 5

multiple interactions

Duloxetine Hydrochloride results in decreased activity of [KCNJ3 mRNA co-treated with KCNJ5 mRNA]

NCBI chr 8:30,724,923...30,753,083
Ensembl chr 8:30,724,925...30,753,518

G

potassium inwardly-rectifying channel, subfamily J, member 6

multiple interactions

Duloxetine Hydrochloride results in decreased activity of [KCNJ3 mRNA co-treated with KCNJ6 mRNA]

NCBI chr11:34,061,702...34,308,758
Ensembl chr11:34,061,708...34,308,758

G

NFE2 like bZIP transcription factor 2

affects localization

Duloxetine Hydrochloride affects the localization of NFE2L2 protein

NCBI chr 3:60,594,239...60,621,712
Ensembl chr 3:60,594,242...60,621,737

G

prolactin

increases expression

Duloxetine Hydrochloride results in increased expression of PRL protein

NCBI chr17:37,859,999...37,870,062
Ensembl chr17:37,860,007...37,870,062

4-methyl-3-[[1-oxo-2-(propylamino)propyl]amino]-2-thiophenecarboxylic acid methyl ester

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

BCL2 associated X, apoptosis regulator

multiple interactions

Carticaine inhibits the reaction [Lipopolysaccharides results in increased expression of BAX protein]

NCBI chr 1:95,940,001...95,945,407
Ensembl chr 1:95,938,808...95,945,368

G

BCL2, apoptosis regulator

multiple interactions

Carticaine inhibits the reaction [Lipopolysaccharides results in decreased expression of BCL2 protein]

NCBI chr13:22,689,783...22,853,920
Ensembl chr13:22,684,989...22,853,743
Ensembl chr13:22,684,989...22,853,743

G

calcitonin-related polypeptide alpha

increases secretion

Carticaine results in increased secretion of CALCA protein

NCBI chr 1:168,878,212...168,883,176
Ensembl chr 1:168,878,214...168,883,105

G

caspase 1

multiple interactions

Carticaine inhibits the reaction [Lipopolysaccharides results in increased expression of CASP1 protein]

NCBI chr 8:2,587,812...2,597,403
Ensembl chr 8:2,587,831...2,597,383

G

interleukin 1 beta

multiple interactions

Carticaine inhibits the reaction [Lipopolysaccharides results in increased expression of IL1B protein]

NCBI chr 3:116,577,005...116,583,386
Ensembl chr 3:116,577,010...116,583,415

G

interleukin 6

multiple interactions

Carticaine inhibits the reaction [Lipopolysaccharides results in increased expression of IL6 protein]

NCBI chr 4:5,214,602...5,219,178
Ensembl chr 4:5,213,394...5,219,178

G

myeloperoxidase

multiple interactions

Carticaine inhibits the reaction [Lipopolysaccharides results in increased activity of MPO protein]

NCBI chr10:72,594,883...72,608,862
Ensembl chr10:72,594,661...72,604,819

G

MYD88, innate immune signal transduction adaptor

multiple interactions

Carticaine inhibits the reaction [Lipopolysaccharides results in increased expression of MYD88 protein]

NCBI chr 8:119,074,439...119,078,508
Ensembl chr 8:119,074,437...119,079,415

G

NFKB inhibitor alpha

multiple interactions

Carticaine inhibits the reaction [Lipopolysaccharides results in increased phosphorylation of NFKBIA protein]

NCBI chr 6:72,858,713...72,861,941
Ensembl chr 6:72,858,712...72,861,941

G

NLR family, pyrin domain containing 3

multiple interactions

Carticaine inhibits the reaction [Lipopolysaccharides results in increased expression of NLRP3 protein]

NCBI chr10:44,326,770...44,353,814
Ensembl chr10:44,328,566...44,352,811

G

RELA proto-oncogene, NF-kB subunit

multiple interactions

Carticaine inhibits the reaction [Lipopolysaccharides results in increased phosphorylation of RELA protein]

NCBI chr 1:202,925,001...202,935,484
Ensembl chr 1:202,924,945...202,935,484

G

toll-like receptor 4

multiple interactions

Carticaine inhibits the reaction [Lipopolysaccharides results in increased expression of TLR4 protein]

NCBI chr 5:80,145,867...80,159,501
Ensembl chr 5:80,145,826...80,159,628

G

tumor necrosis factor

multiple interactions

Carticaine inhibits the reaction [Lipopolysaccharides results in increased expression of TNF protein]

NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629

G

transient receptor potential cation channel, subfamily V, member 1

increases activity

Carticaine results in increased activity of TRPV1 protein

NCBI chr10:57,851,428...57,876,513
Ensembl chr10:57,851,428...57,876,513

arotinolol

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

catalase

multiple interactions

arotinolol promotes the reaction [Thyroxine results in decreased expression of CAT protein]

NCBI chr 3:89,842,393...89,874,577
Ensembl chr 3:89,842,399...89,874,478

azosemide

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

solute carrier family 12 member 2

decreases activity
multiple interactions

azosemide results in decreased activity of SLC12A2 protein
azosemide inhibits the reaction [SLC12A2 protein results in increased uptake of Rubidium]

PMID:15517342 PMID:29959396

NCBI chr18:51,348,282...51,416,448
Ensembl chr18:51,348,302...51,416,440

batimastat

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

acetylcholinesterase

multiple interactions

batimastat results in decreased metabolism of and results in decreased secretion of ACHE protein

NCBI chr12:19,406,133...19,413,713
Ensembl chr12:19,407,360...19,413,651

G

amphiregulin

decreases secretion
multiple interactions

batimastat results in decreased secretion of AREG protein
batimastat inhibits the reaction [pervanadate results in increased cleavage of AREG protein]; batimastat inhibits the reaction [Tetrachlorodibenzodioxin results in increased secretion of AREG protein]

PMID:9685416 PMID:27117977

NCBI chr14:16,972,185...16,981,443
Ensembl chr14:16,972,187...16,981,535

G

erb-b2 receptor tyrosine kinase 4

multiple interactions

batimastat inhibits the reaction [pervanadate results in increased cleavage of ERBB4 protein]

NCBI chr 9:69,523,733...70,596,743
Ensembl chr 9:69,531,481...70,596,595

G

epiregulin

multiple interactions

batimastat inhibits the reaction [Tetrachlorodibenzodioxin results in increased secretion of EREG protein]

NCBI chr14:17,027,287...17,041,062
Ensembl chr14:17,027,287...17,041,062

G

furin (paired basic amino acid cleaving enzyme)

decreases activity

batimastat results in decreased activity of FURIN protein

NCBI chr 1:134,348,142...134,361,182
Ensembl chr 1:134,348,144...134,364,314

G

interleukin 5 receptor subunit alpha

decreases cleavage

batimastat results in decreased cleavage of IL5RA protein

NCBI chr 4:139,630,652...139,664,593
Ensembl chr 4:139,632,066...139,668,544

G

mitogen activated protein kinase 1

decreases activity
multiple interactions

batimastat results in decreased activity of MAPK1 protein
batimastat inhibits the reaction [NTS protein results in increased phosphorylation of and results in increased activity of MAPK1 protein]; batimastat inhibits the reaction [TAC1 protein results in increased phosphorylation of and results in increased activity of MAPK1 protein]; batimastat inhibits the reaction [Tetrachlorodibenzodioxin results in increased activity of MAPK1 protein]

PMID:15247267 PMID:15319441 PMID:27117977

NCBI chr11:83,957,813...84,023,629
Ensembl chr11:83,957,813...84,023,616

G

mitogen activated protein kinase 3

decreases activity
multiple interactions

batimastat results in decreased activity of MAPK3 protein
batimastat inhibits the reaction [NTS protein results in increased phosphorylation of and results in increased activity of MAPK3 protein]; batimastat inhibits the reaction [TAC1 protein results in increased phosphorylation of and results in increased activity of MAPK3 protein]; batimastat inhibits the reaction [Tetrachlorodibenzodioxin results in increased activity of MAPK3 protein]

PMID:15247267 PMID:15319441 PMID:27117977

NCBI chr 1:181,366,646...181,372,863
Ensembl chr 1:181,366,637...181,372,863

G

neurotensin

multiple interactions

batimastat inhibits the reaction [NTS protein results in increased phosphorylation of and results in increased activity of MAPK1 protein]; batimastat inhibits the reaction [NTS protein results in increased phosphorylation of and results in increased activity of MAPK3 protein]

NCBI chr 7:37,564,944...37,574,350
Ensembl chr 7:37,564,533...37,574,423

G

tachykinin, precursor 1

multiple interactions

batimastat inhibits the reaction [TAC1 protein results in increased phosphorylation of and results in increased activity of MAPK1 protein]; batimastat inhibits the reaction [TAC1 protein results in increased phosphorylation of and results in increased activity of MAPK3 protein]; batimastat inhibits the reaction [TAC1 protein results in increased secretion of TGFA protein]

NCBI chr 4:35,679,183...35,687,180
Ensembl chr 4:35,679,704...35,687,178

G

transforming growth factor alpha

multiple interactions
decreases secretion

batimastat inhibits the reaction [TAC1 protein results in increased secretion of TGFA protein]; batimastat inhibits the reaction [Tetrachlorodibenzodioxin results in increased secretion of TGFA protein]
batimastat results in decreased secretion of TGFA protein

PMID:15319441 PMID:27117977

NCBI chr 4:118,618,043...118,700,897
Ensembl chr 4:118,618,269...118,700,894

G

TIMP metallopeptidase inhibitor 2

decreases activity

batimastat results in decreased activity of TIMP2 protein

NCBI chr10:103,541,199...103,590,611
Ensembl chr10:103,531,505...103,590,611

G

tumor necrosis factor

multiple interactions

batimastat inhibits the reaction [tributyltin results in increased secretion of TNF protein]

NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629

canagliflozin

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

acetylcholinesterase

multiple interactions

Canagliflozin inhibits the reaction [[Streptozocin co-treated with Dietary Fats] results in increased activity of ACHE protein]; Canagliflozin inhibits the reaction [Scopolamine results in increased activity of ACHE protein]

PMID:27566243 PMID:28837785

NCBI chr12:19,406,133...19,413,713
Ensembl chr12:19,407,360...19,413,651

G

cholinergic receptor, muscarinic 1

decreases expression
multiple interactions

Canagliflozin results in decreased expression of CHRM1 protein
Canagliflozin affects the reaction [Scopolamine results in decreased expression of CHRM1 protein]

NCBI chr 1:205,567,226...205,583,001
Ensembl chr 1:205,567,220...205,582,356

G

hepatitis A virus cellular receptor 1

increases expression

Canagliflozin results in increased expression of HAVCR1

NCBI chr10:31,118,667...31,151,730
Ensembl chr10:31,119,088...31,151,698

G

luteinizing hormone subunit beta

increases expression

Canagliflozin results in increased expression of LHB protein

NCBI chr 1:95,898,269...95,901,973
Ensembl chr 1:95,900,984...95,901,972
Ensembl chr 1:95,900,984...95,901,972

G

parathyroid hormone

decreases expression

Canagliflozin results in decreased expression of PTH protein

NCBI chr 1:167,508,121...167,511,530
Ensembl chr 1:167,508,598...167,511,530

G

solute carrier family 5 member 2

decreases activity

Canagliflozin results in decreased activity of SLC5A2 protein

NCBI chr 1:182,847,185...182,853,309
Ensembl chr 1:182,847,106...182,853,306

cefalotin

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

ATP binding cassette subfamily B member 11

multiple interactions

[Cephalothin co-treated with Neomycin] results in increased expression of ABCB11 mRNA

NCBI chr 3:54,016,854...54,112,797
Ensembl chr 3:54,017,127...54,112,730

G

ATP binding cassette subfamily C member 2

multiple interactions

[Cephalothin co-treated with Neomycin] results in increased expression of ABCC2 mRNA

NCBI chr 1:242,664,657...242,723,239
Ensembl chr 1:242,664,657...242,723,238

G

ATP binding cassette subfamily C member 3

multiple interactions

[Cephalothin co-treated with Neomycin] results in increased expression of ABCC3 mRNA

NCBI chr10:79,296,681...79,342,749
Ensembl chr10:79,296,693...79,342,595

G

BCL2 associated X, apoptosis regulator

increases expression

Cephalothin results in increased expression of BAX protein

NCBI chr 1:95,940,001...95,945,407
Ensembl chr 1:95,938,808...95,945,368

G

caspase 3

multiple interactions

Cephalothin results in increased cleavage of and results in increased activity of CASP3 protein

NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648

G

cytochrome P450 family 8 subfamily B member 1

multiple interactions

[Cephalothin co-treated with Neomycin] results in decreased expression of CYP8B1 mRNA

NCBI chr 8:121,578,123...121,580,093
Ensembl chr 8:121,557,062...121,580,166

G

fibroblast growth factor 19

multiple interactions

[Cephalothin co-treated with Neomycin] results in increased expression of FGF15 mRNA

NCBI chr 1:200,056,526...200,060,980
Ensembl chr 1:200,056,644...200,060,287

G

NPC1 like intracellular cholesterol transporter 1

multiple interactions

[Cephalothin co-treated with Neomycin] results in increased expression of NPC1L1 mRNA

NCBI chr14:81,071,448...81,091,113
Ensembl chr14:81,071,451...81,091,113

G

nuclear receptor subfamily 5, group A, member 2

multiple interactions

[Cephalothin co-treated with Neomycin] results in increased expression of NR5A2 mRNA

NCBI chr13:48,313,634...48,433,494
Ensembl chr13:48,316,301...48,433,326

G

solute carrier family 10 member 1

multiple interactions

[Cephalothin co-treated with Neomycin] results in increased expression of SLC10A1 mRNA

NCBI chr 6:100,613,045...100,626,670
Ensembl chr 6:100,613,045...100,626,670

G

solute carrier family 25 member 20

multiple interactions

Cephalothin binds to and results in decreased activity of SLC25A20 protein; Cephalothin inhibits the reaction [SLC25A20 protein results in increased transport of Carnitine]

NCBI chr 8:109,365,056...109,386,512
Ensembl chr 8:109,365,002...109,386,512

G

SLC51 subunit beta

multiple interactions

[Cephalothin co-treated with Neomycin] results in decreased expression of SLC51B mRNA

NCBI chr 8:65,931,891...65,939,953
Ensembl chr 8:65,931,890...65,940,145

G

solute carrier organic anion transporter family member 1B2

multiple interactions

[Cephalothin co-treated with Neomycin] results in increased expression of SLCO1B2 mRNA

NCBI chr 4:174,551,463...174,619,988
Ensembl chr 4:174,551,480...174,619,981

G

tumor protein p53

increases expression

Cephalothin results in increased expression of TP53 protein

NCBI chr10:54,300,070...54,311,525
Ensembl chr10:54,300,048...54,311,524

G

vitamin D receptor

multiple interactions

[Cephalothin co-treated with Neomycin] results in increased expression of VDR mRNA

NCBI chr 7:128,987,981...129,037,677
Ensembl chr 7:128,987,981...129,037,677

dorzolamide hydrochloride

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

carbonic anhydrase 2

multiple interactions

dorzolamide binds to and results in decreased activity of CA2 protein

NCBI chr 2:86,741,625...86,756,766
Ensembl chr 2:86,741,626...86,756,818

G

carbonic anhydrase 3

multiple interactions

dorzolamide binds to and results in decreased activity of CA3 protein

NCBI chr 2:86,770,418...86,780,011
Ensembl chr 2:86,770,420...86,784,280

DuP 697

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

prostaglandin-endoperoxide synthase 1

multiple interactions

DuP 697 inhibits the reaction [Arachidonic Acid results in increased activity of PTGS1 protein]

NCBI chr 3:19,584,015...19,605,589
Ensembl chr 3:19,584,015...19,605,586

G

prostaglandin-endoperoxide synthase 2

multiple interactions
decreases activity

[DuP 697 results in decreased expression of PTGS2] inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased abundance of Dinoprostone]
DuP 697 results in decreased activity of PTGS2 protein

PMID:19397918 PMID:25451575

NCBI chr13:62,163,936...62,172,193
Ensembl chr13:62,163,932...62,172,188

G

TNF receptor superfamily member 10b

increases expression

DuP 697 results in increased expression of TNFRSF10A protein

NCBI chr15:44,840,386...44,868,318
Ensembl chr15:44,840,386...44,867,467

G

vascular endothelial growth factor A

affects secretion

DuP 697 affects the secretion of VEGFA protein

NCBI chr 9:14,955,300...14,970,641
Ensembl chr 9:14,955,300...14,970,641

eprosartan

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

collagen type I alpha 1 chain

decreases expression

eprosartan decreases expression of collagen I-a1 mRNA in high fat high sodium fed SHRSP/A3N rat kidney

RGD

NCBI chr10:79,883,622...79,900,625
Ensembl chr10:79,883,622...79,900,624

G

collagen type III alpha 1 chain

decreases expression

eprosartan decreases expression of collagen III mRNA in high fat high sodium fed SHRSP/A3N rat kidney

RGD

NCBI chr 9:47,374,611...47,410,547
Ensembl chr 9:47,374,593...47,410,547

G

fibronectin 1

decreases expression

eprosartan decreases expression of fibronectin mRNA in high fat high sodium fed SHRSP/A3N rat kidney

RGD

NCBI chr 9:73,196,044...73,264,695
Ensembl chr 9:73,196,044...73,264,678

G

serpin family E member 1

decreases expression

eprosartan decreases expression of plasminogen activator inhibitor -1 mRNA in high fat high sodium fed SHRSP/A3N rat kidney

RGD

NCBI chr12:19,601,272...19,611,657
Ensembl chr12:19,601,272...19,611,657

G

transforming growth factor, beta 1

decreases expression

eprosartan decreases expression of TGFbeta mRNA in high fat high sodium fed SHRSP/A3N rat kidney

RGD

NCBI chr 1:81,196,532...81,212,848
Ensembl chr 1:81,196,532...81,212,847

nocodazole

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

ATP binding cassette subfamily C member 2

decreases expression

Nocodazole results in decreased expression of ABCC2 mRNA; Nocodazole results in decreased expression of ABCC2 protein

NCBI chr 1:242,664,657...242,723,239
Ensembl chr 1:242,664,657...242,723,238

G

ATP binding cassette subfamily C member 3

increases expression

Nocodazole results in increased expression of ABCC3 mRNA

NCBI chr10:79,296,681...79,342,749
Ensembl chr10:79,296,693...79,342,595

G

actin alpha 2, smooth muscle

increases expression
multiple interactions

Nocodazole results in increased expression of ACTA2 mRNA
4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide inhibits the reaction [Nocodazole results in increased expression of ACTA2 mRNA]

NCBI chr 1:231,746,527...231,759,307
Ensembl chr 1:231,746,548...231,759,554

G

aryl hydrocarbon receptor

decreases activity

Nocodazole results in decreased activity of AHR protein

NCBI chr 6:52,234,089...52,271,568
Ensembl chr 6:52,234,089...52,271,568

G

anaphase promoting complex subunit 2

multiple interactions

Nocodazole promotes the reaction [CCAR1 protein binds to ANAPC2 protein]

NCBI chr 3:8,086,434...8,098,182
Ensembl chr 3:8,086,462...8,098,178

G

androgen receptor

multiple interactions
decreases localization

Nocodazole inhibits the reaction [Dihydrotestosterone results in increased localization of AR protein]
Nocodazole results in decreased localization of AR protein

NCBI chr X:63,104,771...63,273,934
Ensembl chr X:63,104,771...63,273,925

G

ATM serine/threonine kinase

multiple interactions

Doxorubicin inhibits the reaction [Nocodazole inhibits the reaction [Hydroxyurea results in increased phosphorylation of ATM protein]]; Nocodazole inhibits the reaction [Hydroxyurea results in increased phosphorylation of ATM protein]

NCBI chr 8:53,828,741...53,932,773
Ensembl chr 8:53,831,093...53,932,437

G

ATPase copper transporting beta

multiple interactions

Nocodazole inhibits the reaction [Copper affects the localization of ATP7B protein]

NCBI chr16:69,952,286...70,024,404
Ensembl chr16:69,951,778...70,023,636

G

aurora kinase A

multiple interactions

[benzyloxycarbonylleucyl-leucyl-leucine aldehyde co-treated with Nocodazole] results in increased expression of and results in increased phosphorylation of AURKA protein; MLN8054 inhibits the reaction [[benzyloxycarbonylleucyl-leucyl-leucine aldehyde co-treated with Nocodazole] results in increased phosphorylation of AURKA protein]

NCBI chr 3:161,128,309...161,144,524
Ensembl chr 3:161,128,313...161,144,390

G

aurora kinase B

multiple interactions

4-(4-(N-benzoylamino)anilino)-6-methoxy-7-(3-(1-morpholino)propoxy)quinazoline inhibits the reaction [[benzyloxycarbonylleucyl-leucyl-leucine aldehyde co-treated with Nocodazole] results in increased phosphorylation of AURKB protein]; [benzyloxycarbonylleucyl-leucyl-leucine aldehyde co-treated with Nocodazole] results in increased phosphorylation of AURKB protein

NCBI chr10:53,744,290...53,750,831
Ensembl chr10:53,745,142...53,750,837

G

BCL2 associated X, apoptosis regulator

increases expression

Nocodazole analog results in increased expression of BAX protein

NCBI chr 1:95,940,001...95,945,407
Ensembl chr 1:95,938,808...95,945,368

G

BCL2, apoptosis regulator

increases phosphorylation
decreases expression
multiple interactions

Nocodazole results in increased phosphorylation of BCL2 protein
Nocodazole analog results in decreased expression of BCL2 protein
TYMP inhibits the reaction [Nocodazole results in increased phosphorylation of BCL2 protein]

PMID:15907805 PMID:28412508

NCBI chr13:22,689,783...22,853,920
Ensembl chr13:22,684,989...22,853,743
Ensembl chr13:22,684,989...22,853,743

G

baculoviral IAP repeat-containing 5

multiple interactions

Nocodazole affects the reaction [BIRC5 protein affects the susceptibility to Melphalan]

NCBI chr10:103,072,530...103,081,382
Ensembl chr10:103,073,408...103,081,380

G

BUB1 mitotic checkpoint serine/threonine kinase

multiple interactions
increases phosphorylation

[Nocodazole co-treated with Caffeine] results in increased expression of BUB1 protein modified form; chromium hexavalent ion inhibits the reaction [Nocodazole results in increased phosphorylation of BUB1 protein]

NCBI chr 3:115,020,254...115,051,650
Ensembl chr 3:115,020,254...115,051,650

G

capping actin protein of muscle Z-line subunit alpha 1

multiple interactions

[CAPZA1 protein co-treated with CAPZA2 protein] results in decreased susceptibility to Nocodazole

NCBI chr 2:192,319,696...192,364,755
Ensembl chr 2:192,319,702...192,364,480

G

capping actin protein of muscle Z-line subunit alpha 2

multiple interactions

[CAPZA1 protein co-treated with CAPZA2 protein] results in decreased susceptibility to Nocodazole

NCBI chr 4:45,978,142...46,014,032
Ensembl chr 4:45,977,807...46,013,864

G

caspase 3

increases cleavage
multiple interactions
decreases expression

Nocodazole results in increased cleavage of CASP3 protein
[Doxorubicin co-treated with Nocodazole co-treated with Hydroxyurea] results in increased cleavage of CASP3 protein; [Nocodazole co-treated with Hydroxyurea] results in increased cleavage of CASP3 protein; Caffeine promotes the reaction [[Doxorubicin co-treated with Nocodazole co-treated with Hydroxyurea] results in increased cleavage of CASP3 protein]; NOTCH1 protein mutant form inhibits the reaction [Caffeine promotes the reaction [[Doxorubicin co-treated with Nocodazole co-treated with Hydroxyurea] results in increased cleavage of CASP3 protein]]
Nocodazole analog results in decreased expression of CASP3 protein

PMID:21903591 PMID:28412508 PMID:31597699

NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648

G

caspase 8

multiple interactions
increases cleavage

Caspase Inhibitors inhibits the reaction [Nocodazole analog results in increased expression of CASP8 protein modified form]
Nocodazole analog results in increased cleavage of CASP8 protein

NCBI chr 9:60,263,863...60,312,542
Ensembl chr 9:60,264,075...60,312,542

G

caspase 9

increases cleavage

Nocodazole analog results in increased cleavage of CASP9 protein

NCBI chr 5:154,108,872...154,126,628
Ensembl chr 5:154,109,046...154,126,626

G

cell division cycle and apoptosis regulator 1

multiple interactions
increases expression

Nocodazole inhibits the reaction [sodium arsenite affects the localization of CCAR1 protein]; Nocodazole promotes the reaction [CCAR1 protein binds to ANAPC2 protein]
Nocodazole results in increased expression of CCAR1 protein

PMID:19073175 PMID:21903591

NCBI chr20:30,685,916...30,728,531
Ensembl chr20:30,685,916...30,728,526

G

C-C motif chemokine ligand 2

increases expression

Nocodazole results in increased expression of CCL2 protein

NCBI chr10:67,005,424...67,007,222
Ensembl chr10:67,005,424...67,007,226

G

cyclin B1

increases expression

Nocodazole analog results in increased expression of CCNB1 protein; Nocodazole results in increased expression of CCNB1 protein

PMID:21670593 PMID:28412508

NCBI chr 2:31,912,190...31,921,163
Ensembl chr 2:31,912,193...31,921,172

G

cyclin-dependent kinase 1

increases expression

Nocodazole analog results in increased expression of CDK1 protein

NCBI chr20:19,266,226...19,281,417
Ensembl chr20:19,266,248...19,281,408

G

chromatin licensing and DNA replication factor 1

multiple interactions

[Nocodazole co-treated with chromium hexavalent ion] results in decreased expression of and results in decreased phosphorylation of CDT1 protein

NCBI chr19:50,620,713...50,625,659
Ensembl chr19:50,620,713...50,625,659

G

CF transmembrane conductance regulator

affects localization
multiple interactions

Nocodazole affects the localization of CFTR protein
Nocodazole inhibits the reaction [Cyclic AMP affects the localization of and results in increased activity of CFTR protein]

PMID:12529251 PMID:15994425

NCBI chr 4:46,561,269...46,728,759
Ensembl chr 4:46,560,885...46,728,756

G

checkpoint kinase 1

decreases expression

Nocodazole results in decreased expression of CHEK1 protein

NCBI chr 8:36,420,565...36,443,477
Ensembl chr 8:36,420,569...36,441,009

G

colony stimulating factor 2

multiple interactions

Nocodazole inhibits the reaction [kaempferol results in increased secretion of CSF2 protein]; Nocodazole inhibits the reaction [Quercetin results in increased secretion of CSF2 protein]

NCBI chr10:38,386,945...38,388,926
Ensembl chr10:38,386,945...38,389,199

G

cytochrome P450, family 1, subfamily a, polypeptide 1

multiple interactions

Nocodazole inhibits the reaction [Tetrachlorodibenzodioxin results in increased activity of CYP1A1 protein]; Nocodazole inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of CYP1A1 mRNA]; Nocodazole inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of CYP1A1 protein]
Nocodazole inhibits the reaction [benzotriphenylene results in increased expression of and results in increased activity of CYP1A1 protein]; Nocodazole inhibits the reaction [benzotriphenylene results in increased expression of CYP1A1 mRNA]

PMID:8190110 PMID:16611024

NCBI chr 8:58,096,021...58,102,130
Ensembl chr 8:58,096,077...58,102,125

G

epidermal growth factor

multiple interactions

Nocodazole inhibits the reaction [EGF protein results in increased expression of PSA mRNA]

NCBI chr 2:218,219,408...218,302,359
Ensembl chr 2:218,219,415...218,302,064

G

Fas ligand

multiple interactions

[TYMP co-treated with Nocodazole] results in decreased expression of FASLG mRNA; [TYMP co-treated with Nocodazole] results in decreased expression of FASLG protein

NCBI chr13:74,151,519...74,172,760
Ensembl chr13:74,154,954...74,162,215

G

F-box protein 5

multiple interactions

[Nocodazole co-treated with chromium hexavalent ion] results in decreased expression of FBXO5 protein

NCBI chr 1:42,196,068...42,202,437
Ensembl chr 1:42,196,068...42,202,437

G

fission, mitochondrial 1

increases expression

Nocodazole results in increased expression of FIS1 protein

NCBI chr12:19,708,560...19,723,392
Ensembl chr12:19,708,558...19,723,377

G

geminin, DNA replication inhibitor

multiple interactions

[Nocodazole co-treated with chromium hexavalent ion] results in increased ubiquitination of GMNN protein

NCBI chr17:40,301,771...40,310,054
Ensembl chr17:40,301,808...40,310,054

G

H2A.X variant histone

increases expression

Nocodazole results in increased expression of H2AX protein modified form

NCBI chr 8:44,671,907...44,673,262
Ensembl chr 8:44,671,786...44,673,239

G

hepcidin antimicrobial peptide

decreases expression

Nocodazole results in decreased expression of HAMP mRNA

NCBI chr 1:86,170,926...86,172,865
Ensembl chr 1:86,170,901...86,172,891

G

heat shock protein family A (Hsp70) member 5

increases expression

Nocodazole results in increased expression of HSPA5 protein

NCBI chr 3:18,055,507...18,059,969
Ensembl chr 3:18,055,405...18,059,891

G

interleukin 6 receptor

increases expression

Nocodazole results in increased expression of IL6R protein modified form

NCBI chr 2:175,289,157...175,347,719
Ensembl chr 2:175,298,686...175,347,536

G

Jun proto-oncogene, AP-1 transcription factor subunit

increases phosphorylation
multiple interactions

Nocodazole results in increased phosphorylation of JUN protein
TP53 protein affects the reaction [Nocodazole results in increased phosphorylation of JUN protein]

NCBI chr 5:109,894,175...109,897,268
Ensembl chr 5:109,893,145...109,897,656

G

kallikrein 1-related peptidase C10

multiple interactions

Nocodazole inhibits the reaction [Dihydrotestosterone results in increased expression of KLK3 mRNA]

NCBI chr 1:94,402,993...94,407,052
Ensembl chr 1:94,402,993...94,407,052

G

leucine carboxyl methyltransferase 1

decreases response to substance

LCMT1 results in decreased susceptibility to Nocodazole

NCBI chr 1:177,904,119...177,960,111
Ensembl chr 1:177,904,139...177,960,112

G

leucine zipper tumor suppressor 1

affects response to substance

LZTS1 protein affects the susceptibility to Nocodazole

NCBI chr16:20,542,756...20,598,204
Ensembl chr16:20,542,809...20,598,203

G

mitogen activated protein kinase 1

multiple interactions

2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Nocodazole results in increased phosphorylation of and results in increased activity of MAPK1 protein]; Nocodazole results in increased phosphorylation of and results in increased activity of MAPK1 protein; TYMP affects the reaction [Nocodazole results in increased phosphorylation of and results in increased activity of MAPK1 protein]; U 0126 inhibits the reaction [Nocodazole results in increased phosphorylation of and results in increased activity of MAPK1 protein]
Nocodazole inhibits the reaction [NGF protein results in increased activity of MAPK1 protein]

PMID:15907805 PMID:17822405

NCBI chr11:83,957,813...84,023,629
Ensembl chr11:83,957,813...84,023,616

G

mitogen activated protein kinase 3

multiple interactions

2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Nocodazole results in increased phosphorylation of and results in increased activity of MAPK3 protein]; Nocodazole results in increased phosphorylation of and results in increased activity of MAPK3 protein; TYMP affects the reaction [Nocodazole results in increased phosphorylation of and results in increased activity of MAPK3 protein]; U 0126 inhibits the reaction [Nocodazole results in increased phosphorylation of and results in increased activity of MAPK3 protein]
Nocodazole inhibits the reaction [NGF protein results in increased activity of MAPK3 protein]

PMID:15907805 PMID:17822405

NCBI chr 1:181,366,646...181,372,863
Ensembl chr 1:181,366,637...181,372,863

G

mitogen-activated protein kinase 8

multiple interactions
increases phosphorylation

TP53 protein affects the reaction [Nocodazole results in increased phosphorylation of MAPK8 protein]

NCBI chr16:8,638,897...8,721,960
Ensembl chr16:8,638,924...8,721,981

G

mitogen-activated protein kinase 9

increases phosphorylation
multiple interactions

Nocodazole results in increased phosphorylation of MAPK9 protein
TP53 protein affects the reaction [Nocodazole results in increased phosphorylation of MAPK9 protein]

NCBI chr10:34,169,661...34,211,138
Ensembl chr10:34,169,675...34,210,178

G

microtubule-associated protein tau

decreases expression

Nocodazole results in decreased expression of MAPT protein

NCBI chr10:89,138,644...89,236,137
Ensembl chr10:89,138,627...89,236,129

G

myelin transcription factor 1

increases phosphorylation

Nocodazole results in increased phosphorylation of MYT1 protein

NCBI chr 3:168,890,466...168,950,341
Ensembl chr 3:168,886,089...168,950,341

G

Nanog homeobox

decreases expression

Nocodazole results in decreased expression of NANOG protein

NCBI chr 4:155,943,737...155,951,116
Ensembl chr 4:155,943,737...155,951,116

G

nerve growth factor

multiple interactions

Nocodazole inhibits the reaction [NGF protein affects the localization of NTRK1 protein]; Nocodazole inhibits the reaction [NGF protein affects the localization of RAP1A protein]; Nocodazole inhibits the reaction [NGF protein results in increased activity of MAPK1 protein]; Nocodazole inhibits the reaction [NGF protein results in increased activity of MAPK3 protein]; Nocodazole inhibits the reaction [NGF protein results in increased activity of RAP1A protein]

NCBI chr 2:189,901,058...189,954,452
Ensembl chr 2:189,901,058...189,954,452

G

notch receptor 1

decreases expression
multiple interactions

Nocodazole results in decreased expression of NOTCH1 protein
BI 2536 inhibits the reaction [Nocodazole results in decreased expression of NOTCH1 protein]; Doxorubicin inhibits the reaction [Nocodazole promotes the reaction [Hydroxyurea results in decreased expression of NOTCH1 protein]]; Nocodazole promotes the reaction [Hydroxyurea results in decreased expression of NOTCH1 protein]; NOTCH1 protein mutant form inhibits the reaction [Caffeine promotes the reaction [[Doxorubicin co-treated with Nocodazole co-treated with Hydroxyurea] results in increased cleavage of CASP3 protein]]

NCBI chr 3:9,277,955...9,323,531
Ensembl chr 3:9,278,086...9,323,531

G

NPC intracellular cholesterol transporter 1

multiple interactions

Nocodazole inhibits the reaction [NPC1 protein results in increased secretion of Daunorubicin]

NCBI chr18:3,379,482...3,425,100
Ensembl chr18:3,379,482...3,425,049

G

nucleophosmin 1

affects phosphorylation

Nocodazole affects the phosphorylation of NPM1 protein

NCBI chr10:17,741,512...17,751,626
Ensembl chr10:17,739,941...17,751,645

G

nuclear receptor subfamily 1, group H, member 4

multiple interactions

Nocodazole inhibits the reaction [pregna-4,17-diene-3,16-dione results in decreased activity of NR1H4 protein]

NCBI chr 7:23,846,122...23,942,085
Ensembl chr 7:23,846,122...23,942,047

G

neurotrophic receptor tyrosine kinase 1

multiple interactions

Nocodazole inhibits the reaction [NGF protein affects the localization of NTRK1 protein]

NCBI chr 2:173,236,961...173,253,806
Ensembl chr 2:173,236,963...173,253,770

G

optineurin

affects localization

Nocodazole affects the localization of OPTN protein

NCBI chr17:73,209,572...73,260,251
Ensembl chr17:73,209,575...73,260,251

G

poly (ADP-ribose) polymerase 1

multiple interactions
increases cleavage

TYMP inhibits the reaction [Nocodazole results in increased cleavage of PARP1 protein]
Nocodazole analog results in increased cleavage of PARP1 protein; Nocodazole results in increased cleavage of PARP1 protein

PMID:15907805 PMID:21903591 PMID:28412508

NCBI chr13:92,307,593...92,339,406
Ensembl chr13:92,307,586...92,339,404

G

polo-like kinase 1

multiple interactions
decreases phosphorylation

[Hydroxyurea co-treated with Nocodazole] affects the expression of and affects the phosphorylation of PLK1 protein; Doxorubicin affects the reaction [[Hydroxyurea co-treated with Nocodazole] affects the expression of and affects the phosphorylation of PLK1 protein]
Nocodazole results in decreased phosphorylation of PLK1 protein

NCBI chr 1:176,716,420...176,726,400
Ensembl chr 1:176,716,420...176,726,400

G

POU class 5 homeobox 1

decreases expression

Nocodazole results in decreased expression of POU5F1 protein

NCBI chr20:3,223,128...3,227,891
Ensembl chr20:3,223,129...3,227,891

G

protein phosphatase 2, regulatory subunit B, alpha

decreases response to substance

PPP2R2A results in decreased susceptibility to Nocodazole

NCBI chr15:41,204,659...41,263,924
Ensembl chr15:41,204,200...41,263,924

G

glutamine-rich 1

multiple interactions
increases phosphorylation

Genistein inhibits the reaction [Nocodazole results in increased phosphorylation of QRICH1 protein]

NCBI chr 8:109,216,900...109,256,472
Ensembl chr 8:109,217,376...109,261,359

G

RAN GTPase activating protein 1

multiple interactions

Nocodazole results in increased phosphorylation of [SUMO1 protein binds to RANGAP1 protein]

NCBI chr 7:113,224,695...113,250,441
Ensembl chr 7:113,224,703...113,250,438

G

RAP1A, member of RAS oncogene family

multiple interactions

Nocodazole inhibits the reaction [NGF protein affects the localization of RAP1A protein]; Nocodazole inhibits the reaction [NGF protein results in increased activity of RAP1A protein]

NCBI chr 2:193,208,631...193,286,513
Ensembl chr 2:193,208,635...193,286,501

G

RELA proto-oncogene, NF-kB subunit

multiple interactions

Nocodazole inhibits the reaction [lipopolysaccharide, E coli O55-B5 affects the localization of RELA protein]

NCBI chr 1:202,925,001...202,935,484
Ensembl chr 1:202,924,945...202,935,484

G

solute carrier family 22 member 2

multiple interactions

Nocodazole inhibits the reaction [SLC22A2 protein results in increased uptake of 4-(4-dimethylaminostyryl)-1-methylpyridinium]

NCBI chr 1:48,121,061...48,163,268
Ensembl chr 1:48,121,061...48,163,268

G

small ubiquitin-like modifier 1

multiple interactions

Nocodazole results in increased phosphorylation of [SUMO1 protein binds to RANGAP1 protein]

NCBI chr 9:61,078,790...61,108,697
Ensembl chr 9:61,077,435...61,108,761

G

transferrin

decreases expression

Nocodazole results in decreased expression of TRF protein

NCBI chr 8:103,789,780...103,816,487
Ensembl chr 8:103,767,995...103,816,511

G

tumor protein p53

multiple interactions
increases expression

TP53 protein affects the reaction [Nocodazole results in increased phosphorylation of JUN protein]; TP53 protein affects the reaction [Nocodazole results in increased phosphorylation of MAPK8 protein]; TP53 protein affects the reaction [Nocodazole results in increased phosphorylation of MAPK9 protein]
Nocodazole analog results in increased expression of TP53 protein; Nocodazole results in increased expression of TP53 protein

PMID:12221076 PMID:21559451 PMID:28412508

NCBI chr10:54,300,070...54,311,525
Ensembl chr10:54,300,048...54,311,524

G

tubulin, alpha 1A

multiple interactions

Nocodazole inhibits the reaction [TUBA1A protein binds to TUBA1A protein]

NCBI chr 7:130,113,214...130,116,880
Ensembl chr 7:130,081,032...130,196,186

G

thymidine phosphorylase

multiple interactions

[TYMP co-treated with Nocodazole] results in decreased expression of FASLG mRNA; [TYMP co-treated with Nocodazole] results in decreased expression of FASLG protein; TYMP affects the reaction [Nocodazole results in increased phosphorylation of and results in increased activity of MAPK1 protein]; TYMP affects the reaction [Nocodazole results in increased phosphorylation of and results in increased activity of MAPK3 protein]; TYMP inhibits the reaction [Nocodazole results in increased cleavage of PARP1 protein]; TYMP inhibits the reaction [Nocodazole results in increased phosphorylation of BCL2 protein]

NCBI chr 7:120,438,768...120,444,088
Ensembl chr 7:120,438,770...120,443,874
Ensembl chr 7:120,438,770...120,443,874

G

vascular endothelial growth factor A

increases expression

Nocodazole results in increased expression of VEGFA protein

NCBI chr 9:14,955,300...14,970,641
Ensembl chr 9:14,955,300...14,970,641

pyrantel

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

cytochrome P450, family 1, subfamily b, polypeptide 1

decreases activity

Pyrantel results in decreased activity of CYP1B1 protein

NCBI chr 6:15,342,312...15,350,886
Ensembl chr 6:15,342,344...15,350,917

G

cytochrome P450, family 2, subfamily d, polypeptide 4

affects metabolic processing

CYP2D6 protein affects the metabolism of Pyrantel

NCBI chr 7:113,882,584...113,891,754
Ensembl chr 7:113,881,618...113,891,759

G

cytochrome P450, family 3, subfamily a, polypeptide 2

decreases activity

Pyrantel results in decreased activity of CYP3A4 protein

NCBI chr12:9,207,978...9,230,064
Ensembl chr12:9,015,383...9,285,008

rivaroxaban

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

actin alpha 2, smooth muscle

multiple interactions

Rivaroxaban inhibits the reaction [Carbon Tetrachloride results in increased expression of ACTA2 protein]

NCBI chr 1:231,746,527...231,759,307
Ensembl chr 1:231,746,548...231,759,554

G

albumin

multiple interactions

Rivaroxaban inhibits the reaction [Carbon Tetrachloride results in decreased expression of ALB protein]

NCBI chr14:17,607,397...17,622,814
Ensembl chr14:17,607,381...17,622,836

G

cytochrome P450, family 3, subfamily a, polypeptide 2

multiple interactions
increases hydroxylation

erdafitinib inhibits the reaction [CYP3A4 protein results in increased hydroxylation of Rivaroxaban]

NCBI chr12:9,207,978...9,230,064
Ensembl chr12:9,015,383...9,285,008

G

cytochrome P450, family 3, subfamily a, polypeptide 9

increases hydroxylation
multiple interactions

CYP3A5 protein results in increased hydroxylation of Rivaroxaban
erdafitinib inhibits the reaction [CYP3A5 protein results in increased hydroxylation of Rivaroxaban]

NCBI chr12:16,806,222...16,846,428
Ensembl chr12:16,806,207...16,846,422

G

coagulation factor X

decreases activity

Rivaroxaban results in decreased activity of F10 protein

NCBI chr16:76,468,834...76,488,141
Ensembl chr16:76,468,838...76,488,141

G

coagulation factor III, tissue factor

multiple interactions

Rivaroxaban inhibits the reaction [Carbon Tetrachloride results in increased expression of F3 protein]; Rivaroxaban inhibits the reaction [Cisplatin results in increased expression of F3 protein]

PMID:30719803 PMID:36122812

NCBI chr 2:209,827,061...209,838,666
Ensembl chr 2:209,826,959...209,838,668

G

glutamic--pyruvic transaminase

multiple interactions

Rivaroxaban inhibits the reaction [Carbon Tetrachloride results in increased expression of GPT protein]; Rivaroxaban inhibits the reaction [Cisplatin results in increased activity of GPT protein]

PMID:30719803 PMID:36122812

NCBI chr 7:108,416,646...108,419,495
Ensembl chr 7:108,416,642...108,419,494

G

hydroxysteroid (17-beta) dehydrogenase 3

multiple interactions

Rivaroxaban inhibits the reaction [Cisplatin results in decreased expression of HSD17B3 mRNA]

NCBI chr17:1,027,229...1,058,554
Ensembl chr17:1,027,229...1,058,554

G

hydroxy-delta-5-steroid dehydrogenase, 3 beta- and steroid delta-isomerase 7

multiple interactions

Rivaroxaban inhibits the reaction [Cisplatin results in decreased expression of HSD3B7 mRNA]

NCBI chr 1:182,412,216...182,415,447
Ensembl chr 1:182,412,151...182,415,442

G

interleukin 1 beta

multiple interactions

Rivaroxaban inhibits the reaction [Carbon Tetrachloride results in increased expression of IL1B protein]; Rivaroxaban inhibits the reaction [Cisplatin results in increased expression of IL1B protein]

PMID:30719803 PMID:36122812

NCBI chr 3:116,577,005...116,583,386
Ensembl chr 3:116,577,010...116,583,415

G

RELA proto-oncogene, NF-kB subunit

multiple interactions

Rivaroxaban inhibits the reaction [Cisplatin results in increased phosphorylation of RELA protein]

NCBI chr 1:202,925,001...202,935,484
Ensembl chr 1:202,924,945...202,935,484

G

steroidogenic acute regulatory protein

multiple interactions

Rivaroxaban inhibits the reaction [Cisplatin results in decreased expression of STAR mRNA]

NCBI chr16:66,267,094...66,274,368
Ensembl chr16:66,264,807...66,271,672

G

transforming growth factor, beta 1

multiple interactions

Rivaroxaban inhibits the reaction [Carbon Tetrachloride results in increased expression of TGFB1 protein]

NCBI chr 1:81,196,532...81,212,848
Ensembl chr 1:81,196,532...81,212,847

G

tumor necrosis factor

multiple interactions

Rivaroxaban inhibits the reaction [Carbon Tetrachloride results in increased expression of TNF protein]; Rivaroxaban inhibits the reaction [Cisplatin results in increased expression of TNF protein]

PMID:30719803 PMID:36122812

NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629

G

vascular cell adhesion molecule 1

multiple interactions

Rivaroxaban inhibits the reaction [Cisplatin results in increased expression of VCAM1 protein]

NCBI chr 2:204,038,120...204,057,852
Ensembl chr 2:204,038,114...204,057,958

sufentanil

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

5-hydroxytryptamine receptor 3A

affects activity

Sufentanil affects the activity of HTR3A protein

NCBI chr 8:49,242,018...49,254,475
Ensembl chr 8:49,242,020...49,254,389

G

proopiomelanocortin

decreases expression

Sufentanil results in decreased expression of POMC protein modified form

NCBI chr 6:26,939,844...26,945,666
Ensembl chr 6:26,939,837...26,945,664

suprofen

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

dehydrogenase/reductase 11

decreases activity

Suprofen results in decreased activity of DHRS11 protein

NCBI chr10:69,698,214...69,708,294
Ensembl chr10:69,698,214...69,708,295

G

glutamate-cysteine ligase, catalytic subunit

increases expression

Suprofen results in increased expression of GCLC mRNA

NCBI chr 8:78,629,899...78,668,547
Ensembl chr 8:78,630,127...78,668,544

G

glutamate cysteine ligase, modifier subunit

increases expression

Suprofen results in increased expression of GCLM mRNA

NCBI chr 2:210,347,482...210,367,537
Ensembl chr 2:210,347,482...210,367,535

tenidap

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

arachidonate 5-lipoxygenase

decreases activity
multiple interactions

tenidap results in decreased activity of ALOX5 protein
[tenidap results in decreased activity of ALOX5 protein] which results in decreased chemical synthesis of Leukotriene B4; [tenidap results in decreased activity of ALOX5 protein] which results in increased abundance of 15-hydroxy-5,8,11,13-eicosatetraenoic acid

NCBI chr 4:149,531,329...149,578,696
Ensembl chr 4:149,531,515...149,578,743

G

solute carrier family 26 member 3

decreases activity

tenidap results in decreased activity of SLC26A3 protein

NCBI chr 6:48,023,892...48,064,829
Ensembl chr 6:48,023,892...48,064,772

teniposide

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

ATP binding cassette subfamily C member 1

decreases response to substance

ABCC1 results in decreased susceptibility to Teniposide

NCBI chr10:528,961...655,179
Ensembl chr10:531,812...655,114

G

androgen receptor

multiple interactions

Teniposide binds to and results in decreased activity of AR protein

NCBI chr X:63,104,771...63,273,934
Ensembl chr X:63,104,771...63,273,925

G

cyclin-dependent kinase inhibitor 1A

increases expression

Teniposide results in increased expression of CDKN1A mRNA; Teniposide results in increased expression of CDKN1A protein

NCBI chr20:7,149,177...7,159,727
Ensembl chr20:7,149,217...7,159,585

G

cytochrome P450, family 3, subfamily a, polypeptide 2

decreases methylation
multiple interactions

CYP3A4 protein results in decreased methylation of Teniposide
Cyclosporine inhibits the reaction [CYP3A4 protein results in decreased methylation of Teniposide]; Dexamethasone inhibits the reaction [CYP3A4 protein results in decreased methylation of Teniposide]; Erythromycin inhibits the reaction [CYP3A4 protein results in decreased methylation of Teniposide]; Midazolam inhibits the reaction [CYP3A4 protein results in decreased methylation of Teniposide]

NCBI chr12:9,207,978...9,230,064
Ensembl chr12:9,015,383...9,285,008

G

cytochrome P450, family 3, subfamily a, polypeptide 9

decreases methylation

CYP3A5 protein results in decreased methylation of Teniposide

NCBI chr12:16,806,222...16,846,428
Ensembl chr12:16,806,207...16,846,422

G

estrogen receptor 1

multiple interactions

Teniposide binds to and results in decreased activity of ESR1 protein

NCBI chr 1:41,106,335...41,499,104
Ensembl chr 1:41,210,475...41,495,002

G

estrogen receptor 2

multiple interactions

Teniposide binds to and results in decreased activity of ESR2 protein

NCBI chr 6:94,858,438...94,909,630
Ensembl chr 6:94,809,547...94,908,919

G

fibroblast growth factor 2

decreases response to substance

FGF2 protein results in decreased susceptibility to Teniposide

NCBI chr 2:120,236,328...120,290,673
Ensembl chr 2:120,236,328...120,291,221

G

glutathione S-transferase pi 1

multiple interactions

Teniposide inhibits the reaction [GSTP1 protein results in increased metabolism of 1-chloro-2,4-dinitrobenzene-glutathione conjugate]

NCBI chr 1:201,337,762...201,340,230
Ensembl chr 1:201,321,672...201,340,226

G

microRNA 135b

decreases response to substance

MIR135B mRNA results in decreased susceptibility to Teniposide

NCBI chr13:43,638,857...43,638,953
Ensembl chr13:43,638,857...43,638,953

G

microRNA 196b

decreases response to substance

MIR196B mRNA results in decreased susceptibility to Teniposide

NCBI chr 4:81,330,487...81,330,571
Ensembl chr 4:81,330,487...81,330,571

G

microsomal triglyceride transfer protein

decreases expression
multiple interactions

Teniposide results in decreased expression of MTTP mRNA
Teniposide promotes the reaction [CETP protein results in decreased expression of MTTP mRNA]

NCBI chr 2:226,613,090...226,654,239
Ensembl chr 2:226,613,090...226,654,239

G

MYC proto-oncogene, bHLH transcription factor

decreases expression

Teniposide results in decreased expression of MYC mRNA; Teniposide results in decreased expression of MYC protein

NCBI chr 7:93,593,705...93,598,633
Ensembl chr 7:93,593,705...93,598,630

G

nuclear receptor subfamily 1, group H, member 2

multiple interactions
affects localization
affects response to substance

NR1H2 mutant form inhibits the reaction [Teniposide results in increased expression of CETP mRNA]; Teniposide promotes the reaction [NR1H2 protein results in increased expression of CETP mRNA]
Teniposide affects the localization of NR1H2 protein
NR1H2 protein affects the susceptibility to Teniposide

NCBI chr 1:95,041,967...95,047,358
Ensembl chr 1:95,041,967...95,047,377

G

nuclear receptor subfamily 1, group H, member 3

multiple interactions
increases expression
affects response to substance

NR1H3 mutant form inhibits the reaction [Teniposide results in increased expression of CETP mRNA]; Teniposide promotes the reaction [NR1H3 protein results in increased expression of CETP mRNA]; Teniposide results in increased expression of and affects the localization of NR1H3 protein
Teniposide results in increased expression of NR1H3 mRNA
NR1H3 protein affects the susceptibility to Teniposide

NCBI chr 3:77,158,808...77,168,907
Ensembl chr 3:77,158,808...77,168,722

G

nuclear receptor interacting protein 1

decreases expression

Teniposide results in decreased expression of NRIP1 mRNA; Teniposide results in decreased expression of NRIP1 protein

NCBI chr11:14,895,843...14,979,490
Ensembl chr11:14,895,553...14,981,761

G

ornithine decarboxylase 1

decreases expression

Teniposide results in decreased expression of ODC1 protein

NCBI chr 6:40,329,831...40,336,444
Ensembl chr 6:40,329,964...40,336,440

G

progesterone receptor

multiple interactions

Teniposide binds to and results in decreased activity of PGR protein

NCBI chr 8:6,072,673...6,131,552
Ensembl chr 8:6,072,673...6,131,344

G

retinoid X receptor alpha

multiple interactions

Teniposide promotes the reaction [RXRA protein results in increased expression of CETP mRNA]; Tretinoin promotes the reaction [Teniposide promotes the reaction [RXRA protein results in increased expression of CETP mRNA]]

NCBI chr 3:10,989,832...11,076,366
Ensembl chr 3:10,989,832...11,073,712

G

solute carrier organic anion transporter family, member 2b1

multiple interactions

Teniposide inhibits the reaction [SLCO2B1 protein results in increased uptake of Cascade Blue]

NCBI chr 1:153,959,288...154,007,294
Ensembl chr 1:153,959,293...154,007,353

G

thyroid hormone receptor alpha

multiple interactions

Teniposide binds to and results in decreased activity of THRA protein

NCBI chr10:83,701,885...83,729,408
Ensembl chr10:83,700,755...83,729,936

G

thyroid hormone receptor beta

multiple interactions

Teniposide binds to and results in decreased activity of THRB protein

NCBI chr15:7,685,180...8,031,920
Ensembl chr15:7,685,180...7,882,916

G

DNA topoisomerase II alpha

multiple interactions

TOP2A results in decreased susceptibility to [Cisplatin co-treated with Teniposide]

NCBI chr10:83,945,731...83,976,874
Ensembl chr10:83,945,735...83,976,874

tiagabine

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

aminoadipate aminotransferase

decreases activity

tiagabine results in decreased activity of AADAT protein

NCBI chr16:29,509,392...29,544,332
Ensembl chr16:29,509,394...29,544,332

G

ATP binding cassette subfamily B member 1A

multiple interactions
increases expression

Amino Acids, Peptides, and Proteins inhibits the reaction [tiagabine results in increased expression of ABCB1 protein]

NCBI chr 4:25,357,467...25,529,941
Ensembl chr 4:25,158,362...25,442,709

G

ATP binding cassette subfamily C member 1

increases expression

tiagabine results in increased expression of ABCC1 protein

NCBI chr10:528,961...655,179
Ensembl chr10:531,812...655,114

G

ATP binding cassette subfamily C member 2

increases expression

tiagabine results in increased expression of ABCC2 protein

NCBI chr 1:242,664,657...242,723,239
Ensembl chr 1:242,664,657...242,723,238

G

cytochrome P450, family 19, subfamily a, polypeptide 1

decreases activity

tiagabine results in decreased activity of CYP19A1 protein

NCBI chr 8:54,552,978...54,580,375
Ensembl chr 8:54,553,165...54,580,758

G

kynurenine aminotransferase 1

decreases activity

tiagabine results in decreased activity of KYAT1 protein

NCBI chr 3:13,459,598...13,493,308
Ensembl chr 3:13,459,591...13,493,355

G

solute carrier family 6 member 1

decreases activity

tiagabine results in decreased activity of SLC6A1 protein

NCBI chr 4:147,448,961...147,482,295
Ensembl chr 4:147,466,965...147,482,293

tiaprofenic acid

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

carbonyl reductase 1

increases reduction

CBR1 protein results in increased reduction of tiaprofenic acid

NCBI chr11:32,860,571...32,862,981
Ensembl chr11:32,908,950...32,911,393
Ensembl chr11:32,908,950...32,911,393

G

nuclear receptor subfamily 1, group I, member 2

increases activity

tiaprofenic acid results in increased activity of NR1I2 protein

NCBI chr11:62,460,213...62,496,665
Ensembl chr11:62,460,213...62,496,658

G

UDP glucuronosyltransferase family 2 member B7

multiple interactions
increases glucuronidation

tiaprofenic acid inhibits the reaction [UGT2B7 protein results in increased chemical synthesis of aldosterone 18-glucuronide]; tiaprofenic acid inhibits the reaction [UGT2B7 protein results in increased glucuronidation of Aldosterone]
UGT2B7 protein alternative form results in increased glucuronidation of tiaprofenic acid; UGT2B7 protein results in increased glucuronidation of tiaprofenic acid

PMID:8423545 PMID:8517101 PMID:19740398

NCBI chr14:20,896,682...20,919,604
Ensembl chr14:20,896,682...20,919,604

tienilic acid

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

bone morphogenetic protein 6

increases expression

Ticrynafen results in increased expression of BMP6 mRNA

NCBI chr17:26,318,121...26,469,691
Ensembl chr17:26,318,569...26,470,365

G

cytochrome P450, family 2, subfamily b, polypeptide 3

decreases activity
multiple interactions

Ticrynafen results in decreased activity of CYP2B6 protein
Ticrynafen inhibits the reaction [CYP2B6 protein results in increased chemical synthesis of hydroxybupropion]; Ticrynafen inhibits the reaction [CYP2B6 protein results in increased metabolism of Bupropion]

NCBI chr 1:81,652,762...81,732,153
Ensembl chr 1:81,652,787...81,732,143

G

epiregulin

increases expression

Ticrynafen results in increased expression of EREG mRNA

NCBI chr14:17,027,287...17,041,062
Ensembl chr14:17,027,287...17,041,062

G

heme oxygenase 1

increases expression

Ticrynafen results in increased expression of HMOX1 mRNA

NCBI chr19:13,466,287...13,474,082
Ensembl chr19:13,467,244...13,474,079

G

interleukin 1 alpha

increases expression

Ticrynafen results in increased expression of IL1A mRNA

NCBI chr 3:116,526,601...116,537,055
Ensembl chr 3:116,526,604...116,536,822

G

interleukin 1 beta

increases expression

Ticrynafen results in increased expression of IL1B mRNA

NCBI chr 3:116,577,005...116,583,386
Ensembl chr 3:116,577,010...116,583,415

G

MET proto-oncogene, receptor tyrosine kinase

increases expression

Ticrynafen results in increased expression of MET mRNA

NCBI chr 4:45,790,456...45,898,139
Ensembl chr 4:45,790,791...45,897,876

G

prostaglandin-endoperoxide synthase 2

increases expression

Ticrynafen results in increased expression of PTGS2 mRNA

NCBI chr13:62,163,936...62,172,193
Ensembl chr13:62,163,932...62,172,188

G

renin

increases activity

Ticrynafen results in increased activity of REN protein

NCBI chr13:44,796,260...44,807,491
Ensembl chr13:44,796,091...44,807,489

G

solute carrier family 12 member 2

decreases activity
multiple interactions

Ticrynafen results in decreased activity of SLC12A2 protein
Ticrynafen inhibits the reaction [SLC12A2 protein results in increased uptake of Rubidium]

NCBI chr18:51,348,282...51,416,448
Ensembl chr18:51,348,302...51,416,440

G

solute carrier family 7 member 11

increases expression

Ticrynafen results in increased expression of SLC7A11 mRNA

NCBI chr 2:134,382,002...134,517,622
Ensembl chr 2:133,963,107...134,517,536

G

secretory leukocyte peptidase inhibitor

increases expression

Ticrynafen results in increased expression of SLPI mRNA

NCBI chr 3:153,082,208...153,084,457
Ensembl chr 3:153,082,369...153,084,453

G

UDP glucuronosyltransferase family 1 member A1

increases expression

Ticrynafen results in increased expression of UGT1A1 mRNA

NCBI chr 9:88,801,344...88,808,465
Ensembl chr 9:88,713,184...88,808,465

tiquizium bromide

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

potassium voltage-gated channel subfamily H member 2

decreases activity

thiaton results in decreased activity of KCNH2 protein

NCBI chr 4:10,826,834...10,859,009
Ensembl chr 4:10,826,928...10,859,008

G

myeloperoxidase

multiple interactions

thiaton inhibits the reaction [Indomethacin results in increased activity of MPO protein]

NCBI chr10:72,594,883...72,608,862
Ensembl chr10:72,594,661...72,604,819

G

nitric oxide synthase 2

multiple interactions

thiaton inhibits the reaction [Indomethacin results in increased activity of NOS2 protein]

NCBI chr10:63,815,308...63,851,208
Ensembl chr10:63,815,308...63,851,210

Term paths to the root

Path 1
Term	Annotations
CHEBI ontology	19808
chemical entity	19806
atom	19806
nonmetal atom	19744
sulfur atom	17688
sulfur molecular entity	17688
organosulfur compound	17335
organosulfur heterocyclic compound	10023
thiophenes	220
(1E)-2-(5-chlorothiophen-2-yl)-N-\{(3S)-1-[(1S)-1-methyl-2-morpholin-4-yl-2-oxoethyl]-2-oxopyrrolidin-3-yl\}prop-1-ene-1-sulfonamide	0
(2,5-Dichlorothiophen-3-yl)methyl N-(pyridin-3-ylmethyl)carbamodithioate	0
(2-amino-5-methyl-3-thiophenyl)-thiophen-2-ylmethanone	0
(2R)-5-methyl-2-\{(1R)-2-oxo-1-[(2-thienylacetyl)amino]ethyl\}-3,6-dihydro-2H-1,3-thiazine-4-carboxylic acid	0
(2R)-5-methylene-2-\{(1R)-2-oxo-1-[(2-thienylacetyl)amino]ethyl\}-5,6-dihydro-2H-1,3-thiazine-4-carboxylic acid	0
(2S)-2-\{(R)-carboxy[(2-thienylacetyl)amino]methyl\}-5-methyl-3,6-dihydro-2H-1,3-thiazine-4-carboxylic acid	0
(2S,4S,5R)-2-isobutyl-5-(2-thienyl)-1-[4-(trifluoromethyl)benzoyl]pyrrolidine-2,4-dicarboxylic acid	0
(4R)-4-hydroxy-2-(thien-2-ylmethyl)-3,4-dihydro-2H-thieno[3,2-e][1,2]thiazine-6-sulfonamide 1,1-dioxide	0
(4S)-2-\{(R)-carboxy-[(2-thien-2-ylacetyl)amino]methyl\}-5-methylene-5,6-dihydro-4H-1,3-thiazine-4-carboxylic acid	0
(4S)-4-\{[(5-amino-6-oxo-2-thiophen-2-ylpyrimidin-1(6H)-yl)acetyl]amino\}-2,2-difluoro-5-methyl-N-(2-morpholin-4-ylethyl)-3-oxohexanamide	0
(5'-(but-3-en-1-yn-1-yl)-[2,2'-bithiophen]-5-yl)methanol	0
(5'-(but-3-en-1-yn-1-yl)-[2,2'-bithiophen]-5-yl)methyl acetate	0
(5-bromo-2-thiophenyl)-[4-(3-phenylprop-2-enyl)-1-piperazinyl]methanone	0
(E)-2-(5-chlorothiophen-2-yl)-N-\{(3S)-1-[(1S)-1-methyl-2-morpholin-4-yl-2-oxoethyl]-2-oxopyrrolidin-3-yl\}ethenesulfonamide	0
(E)-5-(hexa-3,5-dien-1-yn-1-yl)-5'-(prop-1-yn-1-yl)-2,2'-bithiophene	0
(Z)-5-[(5-Methyl-2-thienyl)methylene]-2(5H)-furanone	0
1,3-dimethyl-6-[2-(thiophen-2-ylmethylidene)hydrazinyl]pyrimidine-2,4-dione	0
1,4-bis(thiophen-2-ylsulfonyl)piperazine	0
1-(2-methylphenyl)-3-[[(5-methyl-3-thiophenyl)-oxomethyl]amino]thiourea	0
1-(3-methylphenyl)-3-[[(5-methyl-3-thiophenyl)-oxomethyl]amino]thiourea	0
1-(3-methylphenyl)-3-[[oxo-(5-propyl-3-thiophenyl)methyl]amino]thiourea	0
1-(4-chlorophenyl)-3-[4-methyl-2-(thiophen-2-yl)-1,3-thiazol-5-yl]urea	0
1-(5-nitro-2-thiophenyl)piperidine	0
1-[(2-chlorophenyl)methyl]-3-methyl-N-(4-methyl-2-thiazolyl)-5-thieno[2,3-c]pyrazolecarboxamide	0
1-[(5-bromo-2-thiophenyl)sulfonyl]-3-methylpiperidine	0
1-[[(4-ethyl-5-methyl-3-thiophenyl)-oxomethyl]amino]-3-(2-phenylethyl)thiourea	0
1-\{2-[(2-chloro-3-thienyl)methoxy]-2-(2,4-dichlorophenyl)ethyl\}imidazole +	0
1-\{[5-(5-chloro-2-thienyl)isoxazol-3-yl]methyl\}-3-cyano-N-(1-isopropylpiperidin-4-yl)-7-methyl-1H-indole-2-carboxamide	0
1-\{[5-(5-chloro-2-thienyl)isoxazol-3-yl]methyl\}-N-(1-isopropylpiperidin-4-yl)-1H-indole-2-carboxamide	0
1-butyl-3-[[(4,5-dimethyl-3-thiophenyl)-oxomethyl]amino]thiourea	0
1-butyl-3-[[oxo-(5-propan-2-yl-3-thiophenyl)methyl]amino]thiourea	0
1-chloro-3-(5'-(penta-1,3-diyn-1-yl)-[2,2'-bithiophen]-5-yl)prop-2-yn-1-ol	0
1-cyclohexyl-3-[[oxo(thiophen-2-yl)methyl]amino]thiourea	0
1-methyl-N-[2-(4-methylpentan-2-yl)-3-thienyl]-3-(trifluoromethyl)pyrazole-4-carboxamide +	0
2,2'-bithiophenes +	0
2,5-Dichlorothiophene-3-sulfonamide	0
2,5-Dimethylthiophene	0
2,5-dichloro-N-[5-(4-fluorophenyl)-1,3,4-oxadiazol-2-yl]-3-thiophenecarboxamide	0
2-(2-chlorophenyl)-5-(5-methyl-2-thienyl)-1,3,4-oxadiazole	0
2-(4-\{5-[(1H-benzimidazol-2-ylamino)methyl]thiophen-2-yl\}-1,3-thiazol-2-yl)guanidine	0
2-(5-butylthiophen-2-yl)-2,5-dihydropyrazolo[4,3-c]quinolin-3-one	0
2-(5-chlorothiophen-2-yl)-N-\{(3S)-1-[(1S)-1-methyl-2-morpholin-4-yl-2-oxoethyl]-2-oxopyrrolidin-3-yl\}ethanesulfonamide	0
2-(Buta-1,3-diynyl)-5-(but-3-en-1-ynyl) thiophene	0
2-(carbamoylamino)-5-(4-fluorophenyl)-3-thiophenecarboxamide	0
2-Amino-3-Cyano-4-Methyl-5-Carbmethoxy Thiophene	0
2-Pentylthiophene	0
2-Thiophenesulfonamide	0
2-[2-[[2-[(3-carbamoyl-5,6-dihydro-4H-cyclopenta[b]thiophen-2-yl)amino]-2-oxoethyl]thio]-4-thiazolyl]acetic acid ethyl ester	0
2-[[1-oxo-2-(1H-1,2,4-triazol-5-ylthio)ethyl]amino]-4-thiophen-2-yl-3-thiophenecarboxylic acid ethyl ester	0
2-[[2-[5-(4-morpholinylsulfonyl)-2-thiophenyl]-1-oxoethyl]amino]-5-phenyl-3-thiophenecarboxamide	0
2-[[2-[[4-(2-furanylmethyl)-5-(phenylmethyl)-1,2,4-triazol-3-yl]thio]-1-oxoethyl]amino]-5,6-dihydro-4H-cyclopenta[b]thiophene-3-carboxamide	0
2-[[2-[[5-(4-ethylanilino)-1,3,4-thiadiazol-2-yl]thio]-1-oxoethyl]amino]-3-thiophenecarboxamide	0
2-[[cyclohexyl(oxo)methyl]amino]-3-thiophenecarboxamide	0
2-[[oxo(thiophen-2-yl)methyl]amino]-4,5,6,7-tetrahydro-1-benzothiophene-3-carboxylic acid propan-2-yl ester	0
2-[[oxo(thiophen-2-yl)methyl]amino]-6-propyl-4,5,6,7-tetrahydro-1-benzothiophene-3-carboxamide	0
2-\{4-[(4-amino-2-methylpyrimidin-5-yl)methyl]-3-methylthiophen-2-yl\}ethyl trihydrogen diphosphate	0
2-acetyl-5-methylthiophene	0
2-amino-5-[diethylamino(oxo)methyl]-4-methyl-3-thiophenecarboxylic acid propan-2-yl ester	0
2-chloro-N-(2,4-dimethylthiophen-3-yl)-N-(1-methoxypropan-2-yl)acetamide +	0
2-chloro-N-[(5-chloro-2-thiophenyl)methyl]-N-methylacetamide	0
2-methylthiophene	0
2-thienylacetic acid +	0
2-thienylacetonitrile	0
3,4-dimethylthiophene	0
3-(5-Chloro-2-thienyl)-1-methyl-4,5-dihydro-1H-pyrazole	0
3-(5-butyl-2-thiophenyl)-2-cyano-2-propenethioamide	0
3-(5-ethyl-4,5,6,7-tetrahydro-1-benzothiophen-2-yl)-4-prop-2-enyl-1H-1,2,4-triazole-5-thione	0
3-(5-nitro-2-thiophenyl)-1-(1-pyrrolidinyl)-2-propen-1-one	0
3-(5-phenylthiophen-2-yl)prop-2-ynyl acetate	0
3-(carbamoylamino)-5-(3-fluorophenyl)-N-[(3R)-3-piperidinyl]-2-thiophenecarboxamide	0
3-(carbamoylamino)-5-(3-fluorophenyl)-N-[(3S)-3-piperidinyl]-2-thiophenecarboxamide	0
3-Amino-5-(tert-butyl)thiophene-2-carboxamide	0
3-Methylthiophene	0
3-[isopropyl(4-methylbenzoyl)amino]-5-phenylthiophene-2-carboxylic acid	0
3-amino-5-(3-thiophenyl)-2-thiophenecarboxamide	0
3-amino-5-methyl-4-[[3-(4-morpholinyl)propylamino]-oxomethyl]-2-thiophenecarboxylic acid ethyl ester	0
3-chloro-4-propan-2-ylsulfonyl-2-thiophenecarbohydrazide	0
3-ethyl-2-sulfanylidene-5-thiophen-2-yl-1H-thieno[2,3-d]pyrimidin-4-one	0
3-formylthiophene	0
3-methylthiofentanyl +	0
4,5-dimethyl-2-[[oxo(thiophen-2-yl)methyl]amino]-3-thiophenecarboxylic acid ethyl ester	0
4,5-dimethyl-N-(3-thiophenylmethylideneamino)-3-thiophenecarboxamide	0
4,5-dimethyl-N-[[4-(2-methylpropoxy)phenyl]methylideneamino]-3-thiophenecarboxamide	0
4-(2,5-dichlorothiophen-3-yl)pyrimidin-2-amine	0
4-(2-thienyl)butyric acid	0
4-(4-methylpiperazin-1-yl)-N-[5-(2-thienylacetyl)-1,5-dihydropyrrolo[3,4-c]pyrazol-3-yl]benzamide	0
4-(5-bromo-2-thiophenyl)-6-methyl-2-(1-pyrrolyl)pyrimidine	0
4-(5-ethyl-2-thienyl)-4-oxobutyric acid	0
4-([2,2'-bithiophen]-5-yl)but-3-yne-1,2-diol	0
4-Methylthiophene-2-carboxamide	0
4-[(5-bromo-2-thiophenyl)methylideneamino]-3-cyclohexyl-1H-1,2,4-triazole-5-thione	0
4-[5-(4-morpholinylsulfonyl)-2-thiophenyl]-3-phenyl-2H-furan-5-one	0
4-[5-amino-3-methyl-4-[oxo-[3-(trifluoromethyl)phenyl]methyl]-2-thiophenyl]butanoic acid	0
4-\{[2,2'-bithiophene]-5-yl\}-1-chlorobut-3-yn-2-ol	0
4-cyano-3-methyl-5-(4-methylphenyl)-2-thiophenecarbohydrazide	0
4-ethyl-5-methyl-N-[1-[(3-methylphenyl)methyl]-1,2,4-triazol-3-yl]-3-thiophenecarboxamide	0
4-hydroxy-3-(methylthio)-4,5,6,7-tetrahydro-2-benzothiophene-1-carbohydrazide	0
4-oxo-4-(2-thienyl)butyric acid	0
5-(1-Propynyl)-5'-vinyl-2,2'-bithiophene	0
5-(4-Acetoxy-3-oxo-1-butynyl)-2,2'-bithiophene	0
5-(4-chloro-5-phenylthiophen-3-yl)-1,2,5-thiadiazolidin-3-one 1,1-dioxide	0
5-(5-chlorothiophen-2-yl)-N-\{(3S)-1-[(1S)-1-methyl-2-morpholin-4-yl-2-oxoethyl]-2-oxopyrrolidin-3-yl\}-1H-1,2,4-triazole-3-sulfonamide	0
5-(methylsulfanyl)-2-(thiophen-2-yl)-3-(trifluoromethyl)pyridine-4-carbonitrile	0
5-(tert-butyl)-3-[(2-cyanoacetyl)amino]thiophene-2-carboxamide	0
5-Chlorothiophene-2-sulfonamide	0
5-Ethynyl-5'-(1-propynyl)-2,2'-bithiophene	0
5-Methyl-2-thiophenecarboxaldehyde	0
5-[(3-ethoxycarbonyl-4-thiophen-2-yl-2-thiophenyl)amino]-5-oxopentanoic acid	0
5-[(cyclohexylamino)-oxomethyl]-4-methyl-2-[(1-oxo-2-thiophen-2-ylethyl)amino]-3-thiophenecarboxylic acid ethyl ester	0
5-[[3-(1,5-dimethyl-4-pyrazolyl)-1-oxoprop-2-enyl]amino]-3-methylthiophene-2,4-dicarboxylic acid O2-ethyl ester O4-propan-2-yl ester	0
5-[diethylamino(oxo)methyl]-4-methyl-2-(1-oxopentylamino)-3-thiophenecarboxylic acid methyl ester	0
5-amino-3-(4-methoxyphenyl)-7-methyl-4-oxo-1-thieno[3,4-d]pyridazinecarboxylic acid methyl ester	0
5-amino-3-[[[1-(2-furanylmethyl)-5-oxo-3-pyrrolidinyl]-oxomethoxy]methyl]thiophene-2,4-dicarboxylic acid dimethyl ester	0
5-amino-N'-[(3-bromo-4-oxo-1-cyclohexa-2,5-dienylidene)methyl]-4-cyano-3-methyl-2-thiophenecarbohydrazide	0
5-bromo-N-(2-oxolanylmethyl)-2-thiophenesulfonamide	0
5-bromo-N-(2-pyridinylmethyl)-2-thiophenesulfonamide	0
5-bromo-N-(5-cyclohexyl-1,3,4-thiadiazol-2-yl)-2-thiophenecarboxamide	0
5-bromo-N-(5-pyridin-4-yl-1,3,4-oxadiazol-2-yl)-2-thiophenecarboxamide	0
5-bromo-N-(pyridin-4-ylmethyl)-2-thiophenesulfonamide	0
5-bromo-N-[2-(4-chlorophenyl)ethyl]-2-thiophenecarboxamide	0
5-bromo-N-[[[oxo(thiophen-2-yl)methyl]hydrazo]-sulfanylidenemethyl]-2-furancarboxamide	0
5-methyl-N-(1-pyridin-4-ylethylideneamino)-4,5,6,7-tetrahydro-1-benzothiophene-2-carboxamide	0
5-nitro-2-thiophenecarboxylic acid [1-[(3,5-dichloro-2-pyridinyl)amino]-1-oxopropan-2-yl] ester	0
5-nitro-2-thiophenecarboxylic acid [2-oxo-2-(1-phenylethylamino)ethyl] ester	0
5-nitro-2-thiophenecarboxylic acid [2-oxo-2-[(phenylmethyl)amino]ethyl] ester	0
5-nitro-2-thiophenecarboxylic acid [2-oxo-2-[[oxo-[(phenylmethyl)amino]methyl]amino]ethyl] ester	0
6-amino-4-(5-bromo-2-thiophenyl)-3-ethyl-2,4-dihydropyrano[2,3-c]pyrazole-5-carbonitrile	0
6-methyl-2-[2-[(3-methyl-2-thiophenyl)methylidene]hydrazinyl]-1H-pyrimidin-4-one	0
6-methyl-N-(5-methyl-1,3,4-thiadiazol-2-yl)-4,5,6,7-tetrahydro-1-benzothiophene-3-carboxamide	0
Arctinal	0
Arotinolol hydrochloride	0
BMS-214662	0
DuP 697	4
EG00229	0
HTS 01037	0
ML162	0
N'-[(3-phenyl-4-pyrazolylidene)methyl]-2-thiophenecarbohydrazide	0
N'-[4-(3-methoxyphenyl)-2-thiazolyl]-2-thiophenecarbohydrazide	0
N'2-(2-thienylcarbonyl)-5-(1-hexynyl)-2-furancarbohydrazide	0
N,4-dimethyl-5-phenyl-2-thiophenecarboxamide	0
N,N-diethyl-5-thiophen-2-yl-2-thiophenecarboxamide	0
N-(1,3-benzodioxol-5-ylmethyl)-2-[(3-methyl-4-oxo-5-thiophen-2-yl-2-thieno[2,3-d]pyrimidinyl)thio]acetamide	0
N-(1-thiophen-2-ylethylideneamino)-2-thiophenecarboxamide	0
N-(2-furanylmethyl)-5-(4-morpholinyl)-4-phenyl-2-thiophenecarboxamide	0
N-(2-furanylmethyl)-5-methyl-4-phenyl-3-thiophenecarboxamide	0
N-(2-furanylmethylideneamino)-4,5,6,7-tetrahydro-1-benzothiophene-3-carboxamide	0
N-(2-pyridinyl)-4,5,6,7-tetrahydro-1-benzothiophene-3-carboxamide	0
N-(2-tert-butyl-5-oxo-4,6-dihydrothieno[3,4-c]pyrazol-3-yl)-2-thiophenecarboxamide	0
N-(3-Methyl-4-nitro-1,2-oxazol-5-yl)-5-[2-methyl-5-(trifluoromethyl)pyrazol-3-yl]thiophene-2-carboxamide	0
N-(3-carbamoyl-4,5,6,7-tetrahydro-1-benzothiophen-2-yl)-2-methyl-3-pyrazolecarboxamide	0
N-(3-carbamoyl-4,5,6,7-tetrahydro-1-benzothiophen-2-yl)-5-methyl-4-nitro-3-isoxazolecarboxamide	0
N-(3-carbamoyl-5,6-dihydro-4H-cyclopenta[b]thiophen-2-yl)-4-chloro-2-methyl-3-pyrazolecarboxamide	0
N-(3-carbamoyl-5-propyl-2-thiophenyl)-2-methyl-3-furancarboxamide	0
N-(3-carbamoyl-5-propyl-2-thiophenyl)-2-oxolanecarboxamide	0
N-(3-carbamoyl-6-methyl-4,5,6,7-tetrahydro-1-benzothiophen-2-yl)-3-(2-chlorophenyl)-5-methyl-4-isoxazolecarboxamide	0
N-(3-pyridinyl)-2,3-dihydrothieno[3,4-b][1,4]dioxin-5-carboxamide	0
N-(4-\{[(1H-benzotriazol-1-yl)acetyl][(thiophen-3-yl)methyl]amino\}phenyl)propanamide	0
N-(4-tert-butyl-2-thiazolyl)-5-methyl-2-thiophenecarboxamide	0
N-(6-methoxy-3-pyridinyl)-2-thiophenecarboxamide	0
N-(6-methoxy-3-pyridinyl)-3-methyl-2-thiophenecarboxamide	0
N-[(1S)-2-amino-1-(2,4-dichlorobenzyl)ethyl]-5-[2-(methylamino)pyrimidin-4-yl]thiophene-2-carboxamide	0
N-[(2-bromophenyl)methyl]-2-thiophenecarboxamide	0
N-[(2-ethyl-1-piperidinyl)-sulfanylidenemethyl]-2-thiophenecarboxamide	0
N-[(2-fluorophenyl)methyl]-2-thiophenecarboxamide	0
N-[(2-fluorophenyl)methylideneamino]-4,5,6,7-tetrahydro-1-benzothiophene-3-carboxamide	0
N-[(2R,4aR,12aR)-2-[2-[(3-methoxyphenyl)methylamino]-2-oxoethyl]-5-methyl-6-oxo-2,3,4,4a,12,12a-hexahydropyrano[2,3-c][1,5]benzoxazocin-8-yl]-2-thiophenecarboxamide	0
N-[(2R,4aR,12aS)-2-[2-[(3-methoxyphenyl)methylamino]-2-oxoethyl]-5-methyl-6-oxo-2,3,4,4a,12,12a-hexahydropyrano[2,3-c][1,5]benzoxazocin-8-yl]-2-thiophenecarboxamide	0
N-[(2R,4aS,12aR)-2-[2-[(3-methoxyphenyl)methylamino]-2-oxoethyl]-5-methyl-6-oxo-2,3,4,4a,12,12a-hexahydropyrano[2,3-c][1,5]benzoxazocin-8-yl]-2-thiophenecarboxamide	0
N-[(2R,4aS,12aS)-2-[2-[(3-methoxyphenyl)methylamino]-2-oxoethyl]-5-methyl-6-oxo-2,3,4,4a,12,12a-hexahydropyrano[2,3-c][1,5]benzoxazocin-8-yl]-2-thiophenecarboxamide	0
N-[(2S,4aR,12aR)-2-[2-[(3-methoxyphenyl)methylamino]-2-oxoethyl]-5-methyl-6-oxo-2,3,4,4a,12,12a-hexahydropyrano[2,3-c][1,5]benzoxazocin-8-yl]-2-thiophenecarboxamide	0
N-[(2S,4aR,12aS)-2-[2-[(3-methoxyphenyl)methylamino]-2-oxoethyl]-5-methyl-6-oxo-2,3,4,4a,12,12a-hexahydropyrano[2,3-c][1,5]benzoxazocin-8-yl]-2-thiophenecarboxamide	0
N-[(2S,4aS,12aR)-2-[2-[(3-methoxyphenyl)methylamino]-2-oxoethyl]-5-methyl-6-oxo-2,3,4,4a,12,12a-hexahydropyrano[2,3-c][1,5]benzoxazocin-8-yl]-2-thiophenecarboxamide	0
N-[(2S,4aS,12aS)-2-[2-[(3-methoxyphenyl)methylamino]-2-oxoethyl]-5-methyl-6-oxo-2,3,4,4a,12,12a-hexahydropyrano[2,3-c][1,5]benzoxazocin-8-yl]thiophene-2-carboxamide	0
N-[(3,5,5-trimethyl-1-cyclohex-2-enylidene)amino]-2-thiophenecarboxamide	0
N-[(3-fluorophenyl)methylideneamino]-4,5,6,7-tetrahydro-1-benzothiophene-3-carboxamide	0
N-[(3-methyl-2-thiophenyl)methylideneamino]-2-thiophenecarboxamide	0
N-[(5-\{2-[(6R)-2-amino-4-oxo-3,4,5,6,7,8-hexahydropyrido[2,3-d]pyrimidin-6-yl]ethyl\}thiophen-2-yl)carbonyl]-L-glutamic acid	0
N-[(5-acetyl-3-thienyl)methyl]-2-chloroacetamide semicarbazone	0
N-[(5R)-5-(3,4-dichlorobenzyl)-4-oxo-2-thioxo-1,3-thiazolidin-3-yl]thiophene-2-sulfonamide	0
N-[(R)-[(1R,2R)-2-butylcyclopropyl]-(4-chlorophenyl)methyl]-2-thiophenecarboxamide	0
N-[1-methyl-3-(trifluoromethyl)-5-thieno[2,3-c]pyrazolyl]carbamic acid 2,2-dimethylpropyl ester	0
N-[2,2-dimethyl-3-[[oxo(thiophen-2-yl)methyl]amino]propyl]-2-thiophenecarboxamide	0
N-[2-(4-fluorophenyl)ethyl]-5-methyl-2-thiophenecarboxamide	0
N-[2-(cyclohexylamino)-2-oxo-1-thiophen-2-ylethyl]-2,2,2-trifluoro-N-(4-methylphenyl)acetamide	0
N-[3-(3,5-dimethyl-1-piperidinyl)propyl]-4,5,6,7-tetrahydro-1-benzothiophene-3-carboxamide	0
N-[3-[(cyclopropylamino)-oxomethyl]-4,5,6,7,8,9-hexahydrocycloocta[b]thiophen-2-yl]-2-furancarboxamide	0
N-[3-[oxo-(3-pyridinylmethylamino)methyl]-4,5,6,7-tetrahydro-1-benzothiophen-2-yl]-2-furancarboxamide	0
N-[3-carbamoyl-5-[diethylamino(oxo)methyl]-4-methyl-2-thiophenyl]carbamic acid methyl ester	0
N-[5-(2,3-dihydro-1,4-dioxin-5-yl)-1,3,4-oxadiazol-2-yl]-5-nitro-2-thiophenecarboxamide	0
N-[5-(2-oxolanyl)-1,3,4-thiadiazol-2-yl]-2-thiophenecarboxamide	0
N-[5-(3-methoxyphenyl)-1,3,4-thiadiazol-2-yl]-2-thiophenecarboxamide	0
N-[5-[(4-chlorophenoxy)methyl]-1,3,4-thiadiazol-2-yl]-2-thiophenecarboxamide	0
N-[[(5-chloro-2-pyridinyl)amino]-sulfanylidenemethyl]-2-thiophenecarboxamide	0
N-[cyano(2-thienyl)methyl]-4-ethyl-2-(ethylamino)-1,3-thiazole-5-carboxamide +	0
N-\{3-[4-(3-aminopropyl)piperazin-1-yl]propyl\}-3-(2-thiophen-2-ylacetylamino)-5-(3,4,5-trihydroxy-6-hydroxymethyltetrahydropyran-2-yloxy)benzamide	0
N-\{4-[(1H-benzotriazol-1-ylacetyl)(thiophen-3-ylmethyl)amino]phenyl\}-2-methylpropanamide	0
N-\{[5-(1-benzofuran-2-yl)thiophen-2-yl]methyl\}-N-[(2,4-dichlorophenyl)carbonyl]-L-phenylalanine	0
N-butyl-N(2)-(2-thienylacetyl)-L-alaninamide	0
N-butyl-N(2)-(2-thienylacetyl)-L-cysteinamide	0
N-butyl-N(2)-(2-thienylacetyl)-L-serinamide	0
N-ethyl-3-(1-pyrrolyl)-2-thiophenecarboxamide	0
N-methyl-5-phenyl-2-thiophenecarboxamide	0
N-propyl-N-(5-pyridin-4-yl-1,3,4-thiadiazol-2-yl)-2-thiophenecarboxamide	0
N2-[2-(4-pyridyl)ethyl]thiophene-2-carboxamide	0
N2-[2-(tert-butylthio)ethyl]thiophene-2-carboxamide	0
N3-ethyl-2,5-dichlorothiophene-3-sulfonamide	0
OSMI-1	0
SNH	0
[1-(4,5-diphenyl-2-thiophenyl)ethylideneamino]thiourea	0
[3,5-bis[(phenylmethyl)amino]-1,2,4-triazol-1-yl]-thiophen-2-ylmethanone	0
[3-(2-furanyl)-5-(phenylmethylthio)-1,2,4-triazol-1-yl]-thiophen-2-ylmethanone	0
[3-(2-hydroxyphenyl)-5-(4-methoxyphenyl)-3,4-dihydropyrazol-2-yl]-thiophen-2-ylmethanone	0
[3-methyl-4-[oxo(thiophen-2-yl)methyl]-1-piperazinyl]-thiophen-2-ylmethanone	0
[4-(2-pyridinylmethyl)-1-piperazinyl]-thiophen-2-ylmethanone	0
[5-[5-[5-(hydroxymethyl)-2-thiophenyl]-2-furanyl]-2-thiophenyl]methanol	0
[5-hydroxy-3-(4-methoxyphenyl)-5-(trifluoromethyl)-4H-pyrazol-1-yl]-thiophen-2-ylmethanone	0
[[[3-[(4-methylphenyl)methoxy]-2-thiophenyl]-oxomethyl]amino]thiourea	0
\{[5-(3-\{[1-(benzylsulfonyl)piperidin-4-yl]amino\}phenyl)-4-bromo-2-(2H-tetrazol-5-yl)thiophen-3-yl]oxy\}acetic acid	0
aclidinium +	0
arotinolol	1
azosemide	1
batimastat	13
beta-(2-thienyl)-D-alanine	0
canagliflozin +	6
cefalotin +	15
decarboxysuprofen	0
decarboxytiaprofenic acid	0
diethyl 2-\{[2-(2-thienylcarbonyl)hydrazino]methylidene\}malonate	0
dimethenamid OXA	0
dimethenamide ESA	0
dimethylthiambutene	0
dorzolamide +	2
duloxetine +	13
eprosartan +	5
ethyl 2-amino-8H-indeno[2,1-b]thiophene-3-carboxylate	0
formylthiophene	0
hydroxy(phenyl)2-thienylacetic acid	0
isofetamid	0
lotilaner	0
methyl 3-[2-(2-thienyl)acetamido]thiophene-2-carboxylate	0
necrosulfonamide	0
nifurzide	0
nocodazole	70
pyrantel	3
rivaroxaban	15
silthiofam	0
sufentanil	2
suprofen	3
taurosteine	0
tenidap	2
teniposide	23
tenocyclidine	0
thien-2-ylacetate	0
thiencarbazone-methyl	0
thienylfentanyl	0
thifensulfuron-methyl	0
thiophene +	0
thiophenecarboxylic acid +	14
tiagabine	7
tiaprofenic acid	3
tienilic acid	13
tioxazafen	0
tiquizium +	3
triarathene	0
Path 2
Term	Annotations
CHEBI ontology	19808
subatomic particle	19806
composite particle	19806
hadron	19806
baryon	19806
nucleon	19806
atomic nucleus	19806
atom	19806
main group element atom	19756
p-block element atom	19756
carbon group element atom	19705
carbon atom	19702
organic molecular entity	19702
organic molecule	19655
organic cyclic compound	19468
organic heterocyclic compound	18848
organosulfur heterocyclic compound	10023
thiophenes	220
(1E)-2-(5-chlorothiophen-2-yl)-N-\{(3S)-1-[(1S)-1-methyl-2-morpholin-4-yl-2-oxoethyl]-2-oxopyrrolidin-3-yl\}prop-1-ene-1-sulfonamide	0
(2,5-Dichlorothiophen-3-yl)methyl N-(pyridin-3-ylmethyl)carbamodithioate	0
(2-amino-5-methyl-3-thiophenyl)-thiophen-2-ylmethanone	0
(2R)-5-methyl-2-\{(1R)-2-oxo-1-[(2-thienylacetyl)amino]ethyl\}-3,6-dihydro-2H-1,3-thiazine-4-carboxylic acid	0
(2R)-5-methylene-2-\{(1R)-2-oxo-1-[(2-thienylacetyl)amino]ethyl\}-5,6-dihydro-2H-1,3-thiazine-4-carboxylic acid	0
(2S)-2-\{(R)-carboxy[(2-thienylacetyl)amino]methyl\}-5-methyl-3,6-dihydro-2H-1,3-thiazine-4-carboxylic acid	0
(2S,4S,5R)-2-isobutyl-5-(2-thienyl)-1-[4-(trifluoromethyl)benzoyl]pyrrolidine-2,4-dicarboxylic acid	0
(4R)-4-hydroxy-2-(thien-2-ylmethyl)-3,4-dihydro-2H-thieno[3,2-e][1,2]thiazine-6-sulfonamide 1,1-dioxide	0
(4S)-2-\{(R)-carboxy-[(2-thien-2-ylacetyl)amino]methyl\}-5-methylene-5,6-dihydro-4H-1,3-thiazine-4-carboxylic acid	0
(4S)-4-\{[(5-amino-6-oxo-2-thiophen-2-ylpyrimidin-1(6H)-yl)acetyl]amino\}-2,2-difluoro-5-methyl-N-(2-morpholin-4-ylethyl)-3-oxohexanamide	0
(5'-(but-3-en-1-yn-1-yl)-[2,2'-bithiophen]-5-yl)methanol	0
(5'-(but-3-en-1-yn-1-yl)-[2,2'-bithiophen]-5-yl)methyl acetate	0
(5-bromo-2-thiophenyl)-[4-(3-phenylprop-2-enyl)-1-piperazinyl]methanone	0
(E)-2-(5-chlorothiophen-2-yl)-N-\{(3S)-1-[(1S)-1-methyl-2-morpholin-4-yl-2-oxoethyl]-2-oxopyrrolidin-3-yl\}ethenesulfonamide	0
(E)-5-(hexa-3,5-dien-1-yn-1-yl)-5'-(prop-1-yn-1-yl)-2,2'-bithiophene	0
(Z)-5-[(5-Methyl-2-thienyl)methylene]-2(5H)-furanone	0
1,3-dimethyl-6-[2-(thiophen-2-ylmethylidene)hydrazinyl]pyrimidine-2,4-dione	0
1,4-bis(thiophen-2-ylsulfonyl)piperazine	0
1-(2-methylphenyl)-3-[[(5-methyl-3-thiophenyl)-oxomethyl]amino]thiourea	0
1-(3-methylphenyl)-3-[[(5-methyl-3-thiophenyl)-oxomethyl]amino]thiourea	0
1-(3-methylphenyl)-3-[[oxo-(5-propyl-3-thiophenyl)methyl]amino]thiourea	0
1-(4-chlorophenyl)-3-[4-methyl-2-(thiophen-2-yl)-1,3-thiazol-5-yl]urea	0
1-(5-nitro-2-thiophenyl)piperidine	0
1-[(2-chlorophenyl)methyl]-3-methyl-N-(4-methyl-2-thiazolyl)-5-thieno[2,3-c]pyrazolecarboxamide	0
1-[(5-bromo-2-thiophenyl)sulfonyl]-3-methylpiperidine	0
1-[[(4-ethyl-5-methyl-3-thiophenyl)-oxomethyl]amino]-3-(2-phenylethyl)thiourea	0
1-\{2-[(2-chloro-3-thienyl)methoxy]-2-(2,4-dichlorophenyl)ethyl\}imidazole +	0
1-\{[5-(5-chloro-2-thienyl)isoxazol-3-yl]methyl\}-3-cyano-N-(1-isopropylpiperidin-4-yl)-7-methyl-1H-indole-2-carboxamide	0
1-\{[5-(5-chloro-2-thienyl)isoxazol-3-yl]methyl\}-N-(1-isopropylpiperidin-4-yl)-1H-indole-2-carboxamide	0
1-butyl-3-[[(4,5-dimethyl-3-thiophenyl)-oxomethyl]amino]thiourea	0
1-butyl-3-[[oxo-(5-propan-2-yl-3-thiophenyl)methyl]amino]thiourea	0
1-chloro-3-(5'-(penta-1,3-diyn-1-yl)-[2,2'-bithiophen]-5-yl)prop-2-yn-1-ol	0
1-cyclohexyl-3-[[oxo(thiophen-2-yl)methyl]amino]thiourea	0
1-methyl-N-[2-(4-methylpentan-2-yl)-3-thienyl]-3-(trifluoromethyl)pyrazole-4-carboxamide +	0
2,2'-bithiophenes +	0
2,5-Dichlorothiophene-3-sulfonamide	0
2,5-Dimethylthiophene	0
2,5-dichloro-N-[5-(4-fluorophenyl)-1,3,4-oxadiazol-2-yl]-3-thiophenecarboxamide	0
2-(2-chlorophenyl)-5-(5-methyl-2-thienyl)-1,3,4-oxadiazole	0
2-(4-\{5-[(1H-benzimidazol-2-ylamino)methyl]thiophen-2-yl\}-1,3-thiazol-2-yl)guanidine	0
2-(5-butylthiophen-2-yl)-2,5-dihydropyrazolo[4,3-c]quinolin-3-one	0
2-(5-chlorothiophen-2-yl)-N-\{(3S)-1-[(1S)-1-methyl-2-morpholin-4-yl-2-oxoethyl]-2-oxopyrrolidin-3-yl\}ethanesulfonamide	0
2-(Buta-1,3-diynyl)-5-(but-3-en-1-ynyl) thiophene	0
2-(carbamoylamino)-5-(4-fluorophenyl)-3-thiophenecarboxamide	0
2-Amino-3-Cyano-4-Methyl-5-Carbmethoxy Thiophene	0
2-Pentylthiophene	0
2-Thiophenesulfonamide	0
2-[2-[[2-[(3-carbamoyl-5,6-dihydro-4H-cyclopenta[b]thiophen-2-yl)amino]-2-oxoethyl]thio]-4-thiazolyl]acetic acid ethyl ester	0
2-[[1-oxo-2-(1H-1,2,4-triazol-5-ylthio)ethyl]amino]-4-thiophen-2-yl-3-thiophenecarboxylic acid ethyl ester	0
2-[[2-[5-(4-morpholinylsulfonyl)-2-thiophenyl]-1-oxoethyl]amino]-5-phenyl-3-thiophenecarboxamide	0
2-[[2-[[4-(2-furanylmethyl)-5-(phenylmethyl)-1,2,4-triazol-3-yl]thio]-1-oxoethyl]amino]-5,6-dihydro-4H-cyclopenta[b]thiophene-3-carboxamide	0
2-[[2-[[5-(4-ethylanilino)-1,3,4-thiadiazol-2-yl]thio]-1-oxoethyl]amino]-3-thiophenecarboxamide	0
2-[[cyclohexyl(oxo)methyl]amino]-3-thiophenecarboxamide	0
2-[[oxo(thiophen-2-yl)methyl]amino]-4,5,6,7-tetrahydro-1-benzothiophene-3-carboxylic acid propan-2-yl ester	0
2-[[oxo(thiophen-2-yl)methyl]amino]-6-propyl-4,5,6,7-tetrahydro-1-benzothiophene-3-carboxamide	0
2-\{4-[(4-amino-2-methylpyrimidin-5-yl)methyl]-3-methylthiophen-2-yl\}ethyl trihydrogen diphosphate	0
2-acetyl-5-methylthiophene	0
2-amino-5-[diethylamino(oxo)methyl]-4-methyl-3-thiophenecarboxylic acid propan-2-yl ester	0
2-chloro-N-(2,4-dimethylthiophen-3-yl)-N-(1-methoxypropan-2-yl)acetamide +	0
2-chloro-N-[(5-chloro-2-thiophenyl)methyl]-N-methylacetamide	0
2-methylthiophene	0
2-thienylacetic acid +	0
2-thienylacetonitrile	0
3,4-dimethylthiophene	0
3-(5-Chloro-2-thienyl)-1-methyl-4,5-dihydro-1H-pyrazole	0
3-(5-butyl-2-thiophenyl)-2-cyano-2-propenethioamide	0
3-(5-ethyl-4,5,6,7-tetrahydro-1-benzothiophen-2-yl)-4-prop-2-enyl-1H-1,2,4-triazole-5-thione	0
3-(5-nitro-2-thiophenyl)-1-(1-pyrrolidinyl)-2-propen-1-one	0
3-(5-phenylthiophen-2-yl)prop-2-ynyl acetate	0
3-(carbamoylamino)-5-(3-fluorophenyl)-N-[(3R)-3-piperidinyl]-2-thiophenecarboxamide	0
3-(carbamoylamino)-5-(3-fluorophenyl)-N-[(3S)-3-piperidinyl]-2-thiophenecarboxamide	0
3-Amino-5-(tert-butyl)thiophene-2-carboxamide	0
3-Methylthiophene	0
3-[isopropyl(4-methylbenzoyl)amino]-5-phenylthiophene-2-carboxylic acid	0
3-amino-5-(3-thiophenyl)-2-thiophenecarboxamide	0
3-amino-5-methyl-4-[[3-(4-morpholinyl)propylamino]-oxomethyl]-2-thiophenecarboxylic acid ethyl ester	0
3-chloro-4-propan-2-ylsulfonyl-2-thiophenecarbohydrazide	0
3-ethyl-2-sulfanylidene-5-thiophen-2-yl-1H-thieno[2,3-d]pyrimidin-4-one	0
3-formylthiophene	0
3-methylthiofentanyl +	0
4,5-dimethyl-2-[[oxo(thiophen-2-yl)methyl]amino]-3-thiophenecarboxylic acid ethyl ester	0
4,5-dimethyl-N-(3-thiophenylmethylideneamino)-3-thiophenecarboxamide	0
4,5-dimethyl-N-[[4-(2-methylpropoxy)phenyl]methylideneamino]-3-thiophenecarboxamide	0
4-(2,5-dichlorothiophen-3-yl)pyrimidin-2-amine	0
4-(2-thienyl)butyric acid	0
4-(4-methylpiperazin-1-yl)-N-[5-(2-thienylacetyl)-1,5-dihydropyrrolo[3,4-c]pyrazol-3-yl]benzamide	0
4-(5-bromo-2-thiophenyl)-6-methyl-2-(1-pyrrolyl)pyrimidine	0
4-(5-ethyl-2-thienyl)-4-oxobutyric acid	0
4-([2,2'-bithiophen]-5-yl)but-3-yne-1,2-diol	0
4-Methylthiophene-2-carboxamide	0
4-[(5-bromo-2-thiophenyl)methylideneamino]-3-cyclohexyl-1H-1,2,4-triazole-5-thione	0
4-[5-(4-morpholinylsulfonyl)-2-thiophenyl]-3-phenyl-2H-furan-5-one	0
4-[5-amino-3-methyl-4-[oxo-[3-(trifluoromethyl)phenyl]methyl]-2-thiophenyl]butanoic acid	0
4-\{[2,2'-bithiophene]-5-yl\}-1-chlorobut-3-yn-2-ol	0
4-cyano-3-methyl-5-(4-methylphenyl)-2-thiophenecarbohydrazide	0
4-ethyl-5-methyl-N-[1-[(3-methylphenyl)methyl]-1,2,4-triazol-3-yl]-3-thiophenecarboxamide	0
4-hydroxy-3-(methylthio)-4,5,6,7-tetrahydro-2-benzothiophene-1-carbohydrazide	0
4-oxo-4-(2-thienyl)butyric acid	0
5-(1-Propynyl)-5'-vinyl-2,2'-bithiophene	0
5-(4-Acetoxy-3-oxo-1-butynyl)-2,2'-bithiophene	0
5-(4-chloro-5-phenylthiophen-3-yl)-1,2,5-thiadiazolidin-3-one 1,1-dioxide	0
5-(5-chlorothiophen-2-yl)-N-\{(3S)-1-[(1S)-1-methyl-2-morpholin-4-yl-2-oxoethyl]-2-oxopyrrolidin-3-yl\}-1H-1,2,4-triazole-3-sulfonamide	0
5-(methylsulfanyl)-2-(thiophen-2-yl)-3-(trifluoromethyl)pyridine-4-carbonitrile	0
5-(tert-butyl)-3-[(2-cyanoacetyl)amino]thiophene-2-carboxamide	0
5-Chlorothiophene-2-sulfonamide	0
5-Ethynyl-5'-(1-propynyl)-2,2'-bithiophene	0
5-Methyl-2-thiophenecarboxaldehyde	0
5-[(3-ethoxycarbonyl-4-thiophen-2-yl-2-thiophenyl)amino]-5-oxopentanoic acid	0
5-[(cyclohexylamino)-oxomethyl]-4-methyl-2-[(1-oxo-2-thiophen-2-ylethyl)amino]-3-thiophenecarboxylic acid ethyl ester	0
5-[[3-(1,5-dimethyl-4-pyrazolyl)-1-oxoprop-2-enyl]amino]-3-methylthiophene-2,4-dicarboxylic acid O2-ethyl ester O4-propan-2-yl ester	0
5-[diethylamino(oxo)methyl]-4-methyl-2-(1-oxopentylamino)-3-thiophenecarboxylic acid methyl ester	0
5-amino-3-(4-methoxyphenyl)-7-methyl-4-oxo-1-thieno[3,4-d]pyridazinecarboxylic acid methyl ester	0
5-amino-3-[[[1-(2-furanylmethyl)-5-oxo-3-pyrrolidinyl]-oxomethoxy]methyl]thiophene-2,4-dicarboxylic acid dimethyl ester	0
5-amino-N'-[(3-bromo-4-oxo-1-cyclohexa-2,5-dienylidene)methyl]-4-cyano-3-methyl-2-thiophenecarbohydrazide	0
5-bromo-N-(2-oxolanylmethyl)-2-thiophenesulfonamide	0
5-bromo-N-(2-pyridinylmethyl)-2-thiophenesulfonamide	0
5-bromo-N-(5-cyclohexyl-1,3,4-thiadiazol-2-yl)-2-thiophenecarboxamide	0
5-bromo-N-(5-pyridin-4-yl-1,3,4-oxadiazol-2-yl)-2-thiophenecarboxamide	0
5-bromo-N-(pyridin-4-ylmethyl)-2-thiophenesulfonamide	0
5-bromo-N-[2-(4-chlorophenyl)ethyl]-2-thiophenecarboxamide	0
5-bromo-N-[[[oxo(thiophen-2-yl)methyl]hydrazo]-sulfanylidenemethyl]-2-furancarboxamide	0
5-methyl-N-(1-pyridin-4-ylethylideneamino)-4,5,6,7-tetrahydro-1-benzothiophene-2-carboxamide	0
5-nitro-2-thiophenecarboxylic acid [1-[(3,5-dichloro-2-pyridinyl)amino]-1-oxopropan-2-yl] ester	0
5-nitro-2-thiophenecarboxylic acid [2-oxo-2-(1-phenylethylamino)ethyl] ester	0
5-nitro-2-thiophenecarboxylic acid [2-oxo-2-[(phenylmethyl)amino]ethyl] ester	0
5-nitro-2-thiophenecarboxylic acid [2-oxo-2-[[oxo-[(phenylmethyl)amino]methyl]amino]ethyl] ester	0
6-amino-4-(5-bromo-2-thiophenyl)-3-ethyl-2,4-dihydropyrano[2,3-c]pyrazole-5-carbonitrile	0
6-methyl-2-[2-[(3-methyl-2-thiophenyl)methylidene]hydrazinyl]-1H-pyrimidin-4-one	0
6-methyl-N-(5-methyl-1,3,4-thiadiazol-2-yl)-4,5,6,7-tetrahydro-1-benzothiophene-3-carboxamide	0
Arctinal	0
Arotinolol hydrochloride	0
BMS-214662	0
DuP 697	4
EG00229	0
HTS 01037	0
ML162	0
N'-[(3-phenyl-4-pyrazolylidene)methyl]-2-thiophenecarbohydrazide	0
N'-[4-(3-methoxyphenyl)-2-thiazolyl]-2-thiophenecarbohydrazide	0
N'2-(2-thienylcarbonyl)-5-(1-hexynyl)-2-furancarbohydrazide	0
N,4-dimethyl-5-phenyl-2-thiophenecarboxamide	0
N,N-diethyl-5-thiophen-2-yl-2-thiophenecarboxamide	0
N-(1,3-benzodioxol-5-ylmethyl)-2-[(3-methyl-4-oxo-5-thiophen-2-yl-2-thieno[2,3-d]pyrimidinyl)thio]acetamide	0
N-(1-thiophen-2-ylethylideneamino)-2-thiophenecarboxamide	0
N-(2-furanylmethyl)-5-(4-morpholinyl)-4-phenyl-2-thiophenecarboxamide	0
N-(2-furanylmethyl)-5-methyl-4-phenyl-3-thiophenecarboxamide	0
N-(2-furanylmethylideneamino)-4,5,6,7-tetrahydro-1-benzothiophene-3-carboxamide	0
N-(2-pyridinyl)-4,5,6,7-tetrahydro-1-benzothiophene-3-carboxamide	0
N-(2-tert-butyl-5-oxo-4,6-dihydrothieno[3,4-c]pyrazol-3-yl)-2-thiophenecarboxamide	0
N-(3-Methyl-4-nitro-1,2-oxazol-5-yl)-5-[2-methyl-5-(trifluoromethyl)pyrazol-3-yl]thiophene-2-carboxamide	0
N-(3-carbamoyl-4,5,6,7-tetrahydro-1-benzothiophen-2-yl)-2-methyl-3-pyrazolecarboxamide	0
N-(3-carbamoyl-4,5,6,7-tetrahydro-1-benzothiophen-2-yl)-5-methyl-4-nitro-3-isoxazolecarboxamide	0
N-(3-carbamoyl-5,6-dihydro-4H-cyclopenta[b]thiophen-2-yl)-4-chloro-2-methyl-3-pyrazolecarboxamide	0
N-(3-carbamoyl-5-propyl-2-thiophenyl)-2-methyl-3-furancarboxamide	0
N-(3-carbamoyl-5-propyl-2-thiophenyl)-2-oxolanecarboxamide	0
N-(3-carbamoyl-6-methyl-4,5,6,7-tetrahydro-1-benzothiophen-2-yl)-3-(2-chlorophenyl)-5-methyl-4-isoxazolecarboxamide	0
N-(3-pyridinyl)-2,3-dihydrothieno[3,4-b][1,4]dioxin-5-carboxamide	0
N-(4-\{[(1H-benzotriazol-1-yl)acetyl][(thiophen-3-yl)methyl]amino\}phenyl)propanamide	0
N-(4-tert-butyl-2-thiazolyl)-5-methyl-2-thiophenecarboxamide	0
N-(6-methoxy-3-pyridinyl)-2-thiophenecarboxamide	0
N-(6-methoxy-3-pyridinyl)-3-methyl-2-thiophenecarboxamide	0
N-[(1S)-2-amino-1-(2,4-dichlorobenzyl)ethyl]-5-[2-(methylamino)pyrimidin-4-yl]thiophene-2-carboxamide	0
N-[(2-bromophenyl)methyl]-2-thiophenecarboxamide	0
N-[(2-ethyl-1-piperidinyl)-sulfanylidenemethyl]-2-thiophenecarboxamide	0
N-[(2-fluorophenyl)methyl]-2-thiophenecarboxamide	0
N-[(2-fluorophenyl)methylideneamino]-4,5,6,7-tetrahydro-1-benzothiophene-3-carboxamide	0
N-[(2R,4aR,12aR)-2-[2-[(3-methoxyphenyl)methylamino]-2-oxoethyl]-5-methyl-6-oxo-2,3,4,4a,12,12a-hexahydropyrano[2,3-c][1,5]benzoxazocin-8-yl]-2-thiophenecarboxamide	0
N-[(2R,4aR,12aS)-2-[2-[(3-methoxyphenyl)methylamino]-2-oxoethyl]-5-methyl-6-oxo-2,3,4,4a,12,12a-hexahydropyrano[2,3-c][1,5]benzoxazocin-8-yl]-2-thiophenecarboxamide	0
N-[(2R,4aS,12aR)-2-[2-[(3-methoxyphenyl)methylamino]-2-oxoethyl]-5-methyl-6-oxo-2,3,4,4a,12,12a-hexahydropyrano[2,3-c][1,5]benzoxazocin-8-yl]-2-thiophenecarboxamide	0
N-[(2R,4aS,12aS)-2-[2-[(3-methoxyphenyl)methylamino]-2-oxoethyl]-5-methyl-6-oxo-2,3,4,4a,12,12a-hexahydropyrano[2,3-c][1,5]benzoxazocin-8-yl]-2-thiophenecarboxamide	0
N-[(2S,4aR,12aR)-2-[2-[(3-methoxyphenyl)methylamino]-2-oxoethyl]-5-methyl-6-oxo-2,3,4,4a,12,12a-hexahydropyrano[2,3-c][1,5]benzoxazocin-8-yl]-2-thiophenecarboxamide	0
N-[(2S,4aR,12aS)-2-[2-[(3-methoxyphenyl)methylamino]-2-oxoethyl]-5-methyl-6-oxo-2,3,4,4a,12,12a-hexahydropyrano[2,3-c][1,5]benzoxazocin-8-yl]-2-thiophenecarboxamide	0
N-[(2S,4aS,12aR)-2-[2-[(3-methoxyphenyl)methylamino]-2-oxoethyl]-5-methyl-6-oxo-2,3,4,4a,12,12a-hexahydropyrano[2,3-c][1,5]benzoxazocin-8-yl]-2-thiophenecarboxamide	0
N-[(2S,4aS,12aS)-2-[2-[(3-methoxyphenyl)methylamino]-2-oxoethyl]-5-methyl-6-oxo-2,3,4,4a,12,12a-hexahydropyrano[2,3-c][1,5]benzoxazocin-8-yl]thiophene-2-carboxamide	0
N-[(3,5,5-trimethyl-1-cyclohex-2-enylidene)amino]-2-thiophenecarboxamide	0
N-[(3-fluorophenyl)methylideneamino]-4,5,6,7-tetrahydro-1-benzothiophene-3-carboxamide	0
N-[(3-methyl-2-thiophenyl)methylideneamino]-2-thiophenecarboxamide	0
N-[(5-\{2-[(6R)-2-amino-4-oxo-3,4,5,6,7,8-hexahydropyrido[2,3-d]pyrimidin-6-yl]ethyl\}thiophen-2-yl)carbonyl]-L-glutamic acid	0
N-[(5-acetyl-3-thienyl)methyl]-2-chloroacetamide semicarbazone	0
N-[(5R)-5-(3,4-dichlorobenzyl)-4-oxo-2-thioxo-1,3-thiazolidin-3-yl]thiophene-2-sulfonamide	0
N-[(R)-[(1R,2R)-2-butylcyclopropyl]-(4-chlorophenyl)methyl]-2-thiophenecarboxamide	0
N-[1-methyl-3-(trifluoromethyl)-5-thieno[2,3-c]pyrazolyl]carbamic acid 2,2-dimethylpropyl ester	0
N-[2,2-dimethyl-3-[[oxo(thiophen-2-yl)methyl]amino]propyl]-2-thiophenecarboxamide	0
N-[2-(4-fluorophenyl)ethyl]-5-methyl-2-thiophenecarboxamide	0
N-[2-(cyclohexylamino)-2-oxo-1-thiophen-2-ylethyl]-2,2,2-trifluoro-N-(4-methylphenyl)acetamide	0
N-[3-(3,5-dimethyl-1-piperidinyl)propyl]-4,5,6,7-tetrahydro-1-benzothiophene-3-carboxamide	0
N-[3-[(cyclopropylamino)-oxomethyl]-4,5,6,7,8,9-hexahydrocycloocta[b]thiophen-2-yl]-2-furancarboxamide	0
N-[3-[oxo-(3-pyridinylmethylamino)methyl]-4,5,6,7-tetrahydro-1-benzothiophen-2-yl]-2-furancarboxamide	0
N-[3-carbamoyl-5-[diethylamino(oxo)methyl]-4-methyl-2-thiophenyl]carbamic acid methyl ester	0
N-[5-(2,3-dihydro-1,4-dioxin-5-yl)-1,3,4-oxadiazol-2-yl]-5-nitro-2-thiophenecarboxamide	0
N-[5-(2-oxolanyl)-1,3,4-thiadiazol-2-yl]-2-thiophenecarboxamide	0
N-[5-(3-methoxyphenyl)-1,3,4-thiadiazol-2-yl]-2-thiophenecarboxamide	0
N-[5-[(4-chlorophenoxy)methyl]-1,3,4-thiadiazol-2-yl]-2-thiophenecarboxamide	0
N-[[(5-chloro-2-pyridinyl)amino]-sulfanylidenemethyl]-2-thiophenecarboxamide	0
N-[cyano(2-thienyl)methyl]-4-ethyl-2-(ethylamino)-1,3-thiazole-5-carboxamide +	0
N-\{3-[4-(3-aminopropyl)piperazin-1-yl]propyl\}-3-(2-thiophen-2-ylacetylamino)-5-(3,4,5-trihydroxy-6-hydroxymethyltetrahydropyran-2-yloxy)benzamide	0
N-\{4-[(1H-benzotriazol-1-ylacetyl)(thiophen-3-ylmethyl)amino]phenyl\}-2-methylpropanamide	0
N-\{[5-(1-benzofuran-2-yl)thiophen-2-yl]methyl\}-N-[(2,4-dichlorophenyl)carbonyl]-L-phenylalanine	0
N-butyl-N(2)-(2-thienylacetyl)-L-alaninamide	0
N-butyl-N(2)-(2-thienylacetyl)-L-cysteinamide	0
N-butyl-N(2)-(2-thienylacetyl)-L-serinamide	0
N-ethyl-3-(1-pyrrolyl)-2-thiophenecarboxamide	0
N-methyl-5-phenyl-2-thiophenecarboxamide	0
N-propyl-N-(5-pyridin-4-yl-1,3,4-thiadiazol-2-yl)-2-thiophenecarboxamide	0
N2-[2-(4-pyridyl)ethyl]thiophene-2-carboxamide	0
N2-[2-(tert-butylthio)ethyl]thiophene-2-carboxamide	0
N3-ethyl-2,5-dichlorothiophene-3-sulfonamide	0
OSMI-1	0
SNH	0
[1-(4,5-diphenyl-2-thiophenyl)ethylideneamino]thiourea	0
[3,5-bis[(phenylmethyl)amino]-1,2,4-triazol-1-yl]-thiophen-2-ylmethanone	0
[3-(2-furanyl)-5-(phenylmethylthio)-1,2,4-triazol-1-yl]-thiophen-2-ylmethanone	0
[3-(2-hydroxyphenyl)-5-(4-methoxyphenyl)-3,4-dihydropyrazol-2-yl]-thiophen-2-ylmethanone	0
[3-methyl-4-[oxo(thiophen-2-yl)methyl]-1-piperazinyl]-thiophen-2-ylmethanone	0
[4-(2-pyridinylmethyl)-1-piperazinyl]-thiophen-2-ylmethanone	0
[5-[5-[5-(hydroxymethyl)-2-thiophenyl]-2-furanyl]-2-thiophenyl]methanol	0
[5-hydroxy-3-(4-methoxyphenyl)-5-(trifluoromethyl)-4H-pyrazol-1-yl]-thiophen-2-ylmethanone	0
[[[3-[(4-methylphenyl)methoxy]-2-thiophenyl]-oxomethyl]amino]thiourea	0
\{[5-(3-\{[1-(benzylsulfonyl)piperidin-4-yl]amino\}phenyl)-4-bromo-2-(2H-tetrazol-5-yl)thiophen-3-yl]oxy\}acetic acid	0
aclidinium +	0
arotinolol	1
azosemide	1
batimastat	13
beta-(2-thienyl)-D-alanine	0
canagliflozin +	6
cefalotin +	15
decarboxysuprofen	0
decarboxytiaprofenic acid	0
diethyl 2-\{[2-(2-thienylcarbonyl)hydrazino]methylidene\}malonate	0
dimethenamid OXA	0
dimethenamide ESA	0
dimethylthiambutene	0
dorzolamide +	2
duloxetine +	13
eprosartan +	5
ethyl 2-amino-8H-indeno[2,1-b]thiophene-3-carboxylate	0
formylthiophene	0
hydroxy(phenyl)2-thienylacetic acid	0
isofetamid	0
lotilaner	0
methyl 3-[2-(2-thienyl)acetamido]thiophene-2-carboxylate	0
necrosulfonamide	0
nifurzide	0
nocodazole	70
pyrantel	3
rivaroxaban	15
silthiofam	0
sufentanil	2
suprofen	3
taurosteine	0
tenidap	2
teniposide	23
tenocyclidine	0
thien-2-ylacetate	0
thiencarbazone-methyl	0
thienylfentanyl	0
thifensulfuron-methyl	0
thiophene +	0
thiophenecarboxylic acid +	14
tiagabine	7
tiaprofenic acid	3
tienilic acid	13
tioxazafen	0
tiquizium +	3
triarathene	0

paths to the root